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ABSTRACT 
 
The Role of Single Minded 2 Short 
in Mammary Gland Development and Breast Cancer.  (December 2006) 
Hyeong-il Kwak, B.S.,  Chonnam National University; 
M.S., Seoul National University 
Chair of Advisory Committee: Dr.  Weston Porter 
 
     Single minded 2 (Sim2) is a member of the basic helix-loop-helix Per-ARNT-Sim 
(Period-Arylhydrocarbon Nuclear Translocator-Single minded) family.  Human SIM2 is 
involved in the etiology of the Down’s phenotype.  In addition to the physical and 
mental deficiencies associated with DS, it has become apparent that women with DS are 
10-25 times less likely to develop breast cancer in comparison to age-matched normal 
populations.  Such significant effects on breast cancer susceptibility are thought to result 
from gene dosage effects of one or more tumor suppressor genes on chromosome 21.  
Here we report the identification and transcriptional characterization of mouse Sim2s, a 
splice variant of Sim2, which is missing the carboxyl Pro/Ala-rich repressive domain.  
Similar to full-length Sim2, Sim2s interacts with ARNT and to a lesser extent, ARNT2.  
The effects of Sim2s on transcriptional regulation through hypoxia-, dioxin- and central 
midline response elements are different than that of full length Sim2.  Specifically, 
Sim2s exerts a less repressive effect on hypoxia-induced gene expression than full length 
Sim2, but is just as effective as Sim2 at repressing TCDD-induced gene expression from 
a dioxin response element.  Interestingly, Sim2s binds to and activates expression from a 
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central midline response element-controlled reporter through an ARNT transactivation 
domain-dependent mechanism.   
          Forced expression of SIM2s in MDA-MB-435 breast cancer cells significantly 
inhibited proliferation, reduced anchorage-independent growth, and decreased invasive 
potential.   SIM2s directly decreased expression of matrix metalloprotease-3, a known 
mediator of breast cancer metastasis.   In addition, loss of Sim2 in the mouse mammary 
gland increased ductal branching, accelerated lobuloalveolar-like precocious hyperplasia, 
and decreased cell apoptosis, suggesting that SIM2s is a mammary tumor suppressor.  
Sim2-/- mammary glands lose E-cadherin expression, suggesting that Sim2s plays a role 
in regulating E-cadherin/beta-catenin signaling.  Loss of Sim2 in the mammary glands 
also resulted in dramatically increased MMP3 expression.  The mechanism of SIM2s-
mediated repression of MMP3 was found to be due to its ability to inhibit AP-1 binding 
to the MMP3 promoter.   These results suggest that SIM2s contributes to the breast 
cancer protective effects observed in DS individuals. 
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I. INTRODUCTION* 
 
1.1.  Down Syndrome 
     Down Syndrome (DS), which results from trisomy 21, is the most common 
chromosomal abnormality and a leading cause of mental retardation, with a worldwide 
frequency of 1 in 800 births.  DS was first described in 1866 by John Langdon Down.   
In 1959, Jerome Lejeune showed that DS is caused by trisomy of HSA21.  In rapid 
succession, several studies reporting on DS owing to chromosomal translocations that 
involve HSA21 and mosaicism for Ts21 were published (Patterson & Costa, 2005).  It 
has long been recognized that the risk of having a child with trisomy 21 increases with 
maternal age (Penrose, 1933).  For example, the risk of having a liveborn with DS at 
maternal age 30 is 1 in 1,000 and at maternal age 40 is 9 in 1,000 (Hook et al., 1983).  
DS individuals have characteristic phenotypes such as brachycephaly, brachydactyly, 
broad hands, duodenal atresia, epicanthal folds, fifth finger clinodactyly, flat nasal 
bridge, hypotonia, lax ligaments, mental retardation, open mouth, short stature, and wide 
1–2 toe gap (Roizen & Patterson, 2003). 
     The molecular and cellular events linking the presence of an extra chromosome to 
phenotypic features are yet unknown.  It is the central hypothesis that characteristic 
features of DS individuals result from increased expression of genes on chromosome 21 
                                                 
The journal used as a model for this dissertation is Toxicology and Applied Pharmacology. 
* Parts of this section are reprinted from Metz et al., 2006, J Biol Chem, 281(16), 10839-10848, Copyright 
© 2006 by the American Society for Biochemistry and Molecular Biology and Kwak et al., 2006, 
Carcinogenesis, in progress, Copyright © 2006 by Oxford University Press.  
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because of their higher gene dosage.  Accordingly, an essential question in DS research 
is: are all trisomic genes overexpressed in all tissues and at all time points? If not, then 
which genes are overexpressed, and when and where? Answers to these questions are 
critical for determining which genes are relevant to phenotype development, for linking 
expression of specific genes to specific phenotypic features, and to account for 
phenotypic variability (Gardiner, 2004).  The gene content of chromosome 21 is 
estimated to be 329, including 165 experimentally confirmed genes, 150 gene models 
based on expressed sequence tag databases, and 14 computer predictions (Roizen & 
Patterson, 2003).  Given the large number of genes involved, determining which genes 
are overexpressed requires a large-scale approach, which is complicated by the small 
differences in expression level (50%) between normal and DS individuals predicted by 
gene dosage. 
     Interestingly, rare individuals with DS have partial trisomy 21.  Nearly 92% of DS 
individuals have an extra chromosome 21 (Pueschel & Rynders, 1982) in all of their 
cells, resulting in a karyotype with 47 chromosomes, due to trisomy 21.  About 4% of 
DS individuals have smaller portions triplicated because of unbalanced translocations 
(Pueschel & Rynders, 1982).   Mosaicism of the chromosome 21 is present in 2 to 4% of 
the DS individuals.  They present two kinds of cells, one with normal number of 
chromosome, and another with abnormal, i.e.  47.  The main cause of mosaicism is the 
non-disjunction of chromosome 21 during mitosis in embryo.  As lower the number of 
trisomic cells, lower is the phenotypic involvement (Mikkelsen, 1977).  The study of 
individuals with partial trisomy 21 defined the genomic regions that harbor genes 
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associated with some DS phenotypes.  A number of investigators have described a 
‘Down Syndrome critical region (DSCR)’ that specifically contains genes that contribute 
to cognitive defects or other DS features.  The definition of these regions has been 
controversial as there are individuals with partial triplications outside this region who, 
nevertheless, manifest some features of DS (Antonarakis, 2004).  However, the idea of a 
DSCR implies that much of DS could be caused by extra copies of one or a small 
number of genes in this region (Korenberg et al., 1994). 
     It has not been simple to develop a mouse model for DS.  Human chromosome 21 
carries about 329 genes across the 33.5 million bases (Mb) of its long arm and the mouse 
orthologues are distributed across three chromosomes: 10, 16, and 17 (Fig. 1) (Davisson 
et al., 2001; Roizen & Patterson, 2003).   
 
 
Figure 1.  Human chromosome 21 and homologous regions in mouse models.  Regions that are 
syntenic with mouse chromosomes are indicated on the left; those that are trisomic in the major mouse 
models are indicated on the right. Modified from Gardiner, 2004. 
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     The centromere-proximal 30 Mb region of chromosome 21 up to and including the 
ZNF295 gene is orthologous to the telomeric region of mouse chromosome 16 and the 
next two approximately 1-2 Mb segments of chromosome 21 are orthologous to regions 
of mouse chromosomes 17 and 10, respectively (Gardiner, 2004).  Ts65Dn mice have 
three copies of 94 genes orthologous to human chromosome 21 genes, contained within 
chromosome 16 from the Gabpa/App gene cluster to the distal telomere (Reeves et al., 
1995).  Ts1Cje, a second partial trisomy mouse model, is trisomic for 71 orthologs of 
human chromosome 21 genes, within chromosome 16 distal to the superoxide dismutase 
1 (Sod1) gene to the telomere (Fig. 1) (Sago et al., 1998).  Although neither mouse was a 
perfect model for human trisomy 21, there were substantial similarities in phenotype, 
notably craniofacial changes that mimic the human condition, along with 
electrophysiological differences in brain activity and altered behavior. 
     Recently, several groups have examined gene dosage effects of trisomy 21, by 
screening microarrays with RNA from brains of human fetuses with DS (Mao et al., 
2003) or a trisomic mouse models (Amano et al., 2004), by screening a cDNA array 
containing mouse orthologs of human chromosome 21 genes with RNA from several 
tissues of a mouse model (Kahlem et al., 2004), and by using quantitative reverse-
transcriptase-coupled (RT) PCR analysis of RNA from different tissues of a mouse 
model at different ages (Lyle et al., 2004).  The results of all the studies support the 
hypothesis that gene dosage effects exist in DS, but they also show that dosage effects 
may be specific to particular genes, alleles and/or tissues, and that background and 
stochastic or transient effects may be confounding factors (Table 1) (Gardiner, 2004). 
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Table 1.  Overview of studies of gene-dosage effects in trisomies. Modified from Gardiner, 2004. 
Species and strain Humans with DS Ts1Cje mice Ts65Dn mice 
Ages 17-20 weeks gestation postnatal day 0 3-4 months 
Tissues Cerebrum and cortex-
derived astrocyte cell lines 
Whole brain Cortex, mid brain, cerebellum, 
heart, testis, liver, kidney, 
lung, and muscle 
Number of genes on 
trisomic segment 
 71 94 (77tested in 9 tissues) 
Trisomic genes increased 
in expression 
25 (Variation among 
individuals) 
37 (Variation among 
individuals) 
all genes (of 66 with 
detectable expression) except 
in muscle 
Non-trisomic genes with 
altered expression 
  Not determined 
 
 
     Due to improvements in medical care, individuals with DS are living longer, healthier 
lives than was possible just a few decades ago.  As a result, it has become apparent that 
the incidence of cancer in individuals with DS is unique.   Most notably, people with DS 
are more susceptible to childhood leukemias and germ-line cancers, but are more than 
50% less likely to develop solid tumors including cancers of the lung, colon, skin, head 
and neck (Boker et al., 2001;  Hasle et al., 2000a; Hasle et al., 2000b; Hasle et al., 
2000c; Yang et al., 2002a) (Table 2).   Even more striking is the observation that women 
with DS are 10-25 times less likely to develop breast cancer in comparison to age-
matched normal populations (Benard et al., 2005; Hasle et al., 2000a; Hasle et al., 
2000b; Hasle et al., 2000c; Hill et al., 2003; Stage et al., 1998) (Table 3).  Compared to 
an age-matched population, there were no cases of breast cancer in 1278 women with 
DS with 7.3 cases expected (Hasle et al., 2000a).   Another study reported only one case 
of breast cancer in DS, compared with 11.7 expected in an age matched U.S.  population 
(Scholl et al., 1982).    
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Table 2.  Decrease in solid tumors in individuals with Down Syndrome. Adapted from Hasle et al., 
2000. 
 
Age group Observed Expected 
0-9 1 1.42 
10-19 1 1.50 
20-29 1 3.89 
30-39 4 6.47 
40-49 5 11.52 
50-59 8 14.28 
60+ 4 8.67 
Total 24 47.77 
 
 
 
Table 3.  Distribution of solid tumors in individuals with Down Syndrome. Adapted from Hasle et al., 
2000. 
 
Site Observed Expected 
Buccal Cavity 0 1.04 
Digestive System 4 6.52 
Respiratory System 1 4.96 
Breast 0 7.32 
Female Genital Organs 4 5.68 
Male Genital Organs 4 2.82 
Urinary Tract 4 2.97 
Skin 2 8.14 
Other 1 4.75 
Secondary Sites 3 0.92 
Non-Hodgkin’s lymphoma 0 1.41 
Hodgkin’s Disease 0 0.92 
All Solid Tumors 24 47.77 
 
 
     Women with DS rarely become pregnant, increasing their risk for breast cancer; 
however, they experience earlier menopause, leading to a decrease in risk.  Hormonal 
factors alone are unlikely to explain the decreased rate of breast cancer, thus protective 
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factors are more likely to be genetically linked.  These observations have led to the 
hypothesis that one or more tumor suppressor genes are present on chromosome 21 and 
prevent cancer development by gene dosage effects. 
     As introduced above, rare DS individuals carry chromosomal rearrangements 
resulting in triplication of only part of chromosome 21, although most cases of DS are 
attributable to the presence of three full copies of chromosome 21.  Molecular 
characterization of these “partial trisomy” cases has allowed the delineation of a DSCR, 
located at the sub-band 21q22.2, which correlates with many DS abnormalities.  Using 
the exon-trapping technique to isolate potential coding sequences within this region, two 
groups have identified exons that predict an open reading frame that is highly 
homologous to the Drosophila sim gene product.  Based on its chromosomal location 
and sequence, the gene that maps to the DSCR is the human equivalent of the murine 
Sim2 gene (Michaud & Fan, 1997).  DS individuals are characterized by skeleton and 
cranio-facial defects, hypotonia, and heart defects.  In addition, in DS individuals, 
several neural and neurochemical abnormalities were observed involving early 
Alzheimer's disease, mental retardation, hypoplasia of the hippocampus, the cortex and 
the, retarded cortical lamination and myelinization and neurotransmitter alterations.  
These neurological phenotypes may be a consequence of altered growth and/or 
differentiation of neuronal cells during Central Nervous System (CNS) development 
(Rachidi et al., 2005).  Human SIM2, thus, has been thought as a candidate gene in the 
etiology of the Down’s phenotype (Muenke et al., 1995).  This is supported by the 
observation that transgenic mice trisomic for SIM2, with one BAC-containing copy of 
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hSIM2, and two endogenous copies of mSim2, have some aspects of Down’s phenotype, 
exhibiting anxiety-related/reduced exploratory behaviour and reduced sensitivity to pain 
(Chrast et al., 2000).  Neurological abnormalities have been reported in the Ts65Dn 
mouse which has the triplication of a segment of chromosome 16 syntenic to the DSCR 
and containing Sim2 (Reeves et al., 1995).  It is also supported by a study on SIM2 
spatial and temporal expression pattern during human central nervous system 
development, from embryonic to fetal stages.  In embryonic stages, SIM2 was identified 
predominantly in restricted regions of CNS, in ventral part of D1/D2 diencephalic 
neuroepithelium, along the neural tube and in a few cell subsets of dorsal root ganglia.  
In fetal stages, SIM2 showed differential expression in pyramidal and granular cell 
layers of hippocampal formation, in cortical cells and in cerebellar external granular and 
Purkinje cell layers.  SIM2 expression in embryonic and fetal brain could suggest a 
potential role in human CNS development, in agreement with Drosophila and mouse 
Sim mutant phenotypes and with the conservation of the Sim function in CNS 
development from Drosophila to Human.  SIM2 expression in human fetal brain regions, 
which correspond to key structures for cognitive processes, correlates well with the 
behavioral phenotypes of Drosophila Sim mutants and transgenic mice overexpressing 
Sim2.  In addition, SIM2-expressing brain regions correspond to the altered structures in 
DS individuals (Rachidi et al., 2005).  Sim2−/− mice die within 3 days of birth due to 
breathing failure (Goshu et al., 2002), exhibiting reduced efficacy of lung inflation and 
numerous abnormalities within the structural components surrounding the pleural cavity. 
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1.2. Single minded 2 
     Sim is a member of basic helix-loop-helix Per-Arnt-Sim (bHLH-PAS) family that 
activates midline gene transcription and represses lateral CNS gene transcription (Crews, 
1998).  Sim gene was first identified in Drosophila melanogaster as a mutation affecting 
neurogenesis and causing early lethality.  To the contrary, in transgenic flies, 
ubiquitously expressed sim caused many other cells of the ventral neurogenic region to 
differentiate into CNS midline cells (Nambu et al., 1991).  Thus, Drosophila sim is 
proposed to act as a master regulator of midline cell development in the CNS, 
functioning as a transcriptional regulator in cell fate determination (Nambu et al., 1993).  
In Drosophila, expression of dsim is found in midline cells, anterior and posterior to the 
developing ventral cord throughout the germ band, and during post-embryonic 
development in the central complex of the brain (Pielage et al., 2002).   
          Two homologs of dsim, Sim1 and Sim2, have been identified (Ema et al., 1996; 
Moffett et al., 1996).  Sim1 is localized on the proximal region of mouse chromosome 
10, while Sim2 on the very distal end of chomosome 16.  According to the mouse–
human linkage homologies, it is likely that Sim1 maps to human 6q21 and Sim2 to 
21q22 (Fan et al., 1996).  A general feature of the expression of the mammalian Sim 
genes is that some of their sites of expression roughly parallel those of Drosophila sim.  
In Drosophila, sim is expressed in the brain, ventral nerve cord, gut, and muscles (Crews 
et al., 1988).  Similarly, in mouse, Sim1 is expressed in the brain, ventral spinal cord, 
and foregut, and Sim2 is expressed in the brain and in muscles.  In addition, both 
mammalian Sim genes are expressed in the developing mesonephros and, later, the 
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kidney.  Importantly, whereas sim is a key regulator of CNS midline cell development in 
the fly, the mammalian Sim genes are not expressed in floor plate cells of the spinal cord.  
The only expression of the mouse Sim genes in the ventral midline of the CNS is in the 
mammillary area of the diencephalon.  Sim2 is expressed in the forebrain in a restricted 
pattern in the caudal diencephalon at early stages of neural development (Fan et al., 
1996).  The importance of this expression pattern is in showing that the forebrain is 
already regionalized at the two-somite stage, prior to any overt morphological 
specialization of the diencephalons primordium (Fan et al., 1996). 
 
1.3. Basic helix-loop-helix Per-ARNT-Sim 
     The bHLH-PAS proteins comprise a growing family of transcription factors that play 
key roles during development and in sensing and adapting to changes in the environment.  
Individual PAS proteins are known to control morphogenesis, circadian rhythmicity, 
responses to hypoxia and toxin metabolism.  These proteins contain a bHLH motif, 
which mediates dimerization with other bHLH proteins and contributes to determining 
DNA binding specificity.  The PAS domain, named after the founding members of this 
family (Period-Arylhydrocarbon nuclear translocator-Single minded), is a 
multifunctional protein surface responsible for such diverse activities as ligand binding, 
PAS protein dimerization and non-PAS protein interactions (Kewley et al., 2004).  In 
addition to environmental adaptation, some members of the bHLH-PAS family regulate 
development.   
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Figure 2.  Schematic representation of the domain structure of bHLH-PAS family members. 
Modified from Kewley, 2004. 
 
 
     The bHLH-PAS proteins share a conserved sequence structure (Fig. 2).  The bHLH 
domain is located near the amino terminus.  The basic region binds DNA and the HLH 
domain promotes dimerization.  These residues are followed closely by the PAS domain.  
The carboxy-terminal residues contain transcriptional activation domains or repression 
domains.  The PAS domain found in bHLH-PAS proteins is ~260-310 amino acids long; 
it is subdivided into two well-conserved regions, PAS-A and PAS-B, separated by a 
poorly conserved spacer.  Within both the A and B regions lie a copy of a 44-amino acid 
repeat referred to as the PAS repeat (Crews, 1998). 
     The bHLH-PAS family members can be grouped into two classes.  Class I 
bHLH/PAS factors neither homodimerize nor heterodimerize with other Class I factors, 
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and include the aryl hydrocarbon receptor (AhR), the hypoxia inducible factors (HIF; 
HIF-1α, HIF-2α, and HIF-3α) and single minded proteins (SIM1 and SIM2).  To form 
active transcription factor complexes they must dimerize with a Class II bHLH/PAS 
factor, which promiscuously homo- and heterodimerize.  The best characterized Class II 
protein is the ubiquitous ARNT.  Other members of this class include the tissue 
restricted ARNT2, and the circadian rhythm proteins BMAL1 and BMAL2 (Kewley et 
al., 2004). 
     The aryl hydrocarbon receptor (AhR), also known as the Dioxin receptor, is one of 
the best characterised bHLH/PAS proteins.  In its inactive state, the AhR is found in the 
cytoplasm, stably associated with two molecules of heat shock protein 90 (Hsp90), p23 
and hepatitis B virus X-associated protein (XAP2/AIP/Ara9).  Following ligand binding, 
the AhR/Hsp90 complex translocates to the nucleus where Hsp90 is exchanged for 
partner protein ARNT.  The ligand-bound AhR/ARNT heterodimer, then, binds 
xenobiotic response elements (XREs) that contain a –GCGTG- core binding sequence 
(Crews, 1998).   
     The bHLH–PAS proteins play an important role in responding to low oxygen levels 
in vertebrates and probably invertebrates.  Responses to hypoxia are mediated by three 
bHLH/PAS proteins, HIF-1α, HIF-2α (Endothelial PAS domain protein 1) and HIF-3α.  
For example, HIF-1a protein is stabilized under hypoxic conditions by a poorly 
characterized O2 sensing pathway.  It then dimerizes with Arnt and binds hypoxia 
response elements (HREs; ACGTG core sequence) on target genes (Crews & Fan, 1999).  
HIF-1a mediates the physiological response to both hypoglycemia and hypoxia by 
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upregulating genes that encode glycolytic enzymes, erythropoietin (EPO), and vascular 
endothelial growth factor (VEGF) (Semenza, 1998). 
     The trachealess (trh) gene encodes a bHLH-PAS protein that is specifically expressed 
in the developing trachea plus posterior spiracle, salivary gland placode, and salivary 
ducts.  The functional similarity between Sim and Trh is remarkable; both are lineage-
specific regulators, autoregulatory, and bHLH-PAS transcriptional activators.  Work 
described below indicates that Sim and Trh control transcription in a similar fashion by 
binding the same DNA sequence element using Tgo as a dimerization partner (Crews, 
1998). 
     Similar to other members of the bHLH/PAS family, dSim functions as a heterodimer 
with Tango, the Drosophila ortholog of Arnt (Crews et al., 1992).   This complex binds 
central midline elements (CME: -TACGTG-) to regulate genes that direct midline cell 
development and axon growth, such as TGF-β, FGF-receptor and Slit (Lee et al., 1999; 
Estes et al., 2001; Crews et al., 1992) (Fig. 3A).  For example, dSim activates Slit 
secretion from midline cells which blocks axon growth by binding the Slit receptor, 
Roundabout (Robo), to repel axons from crossing the midline or to prevent those that 
have crossed from migrating back (Brose et al., 1999) (Fig. 3B).  Thus, Drosophila CNS 
midline cell regulation of axon branching and development is dependent upon dSim 
regulation of genes involved in cell fate determination and stromal-epithelial 
interactions. 
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Figure 3. Drosophila Sim and development of CNS midline.  dSim functions as a heterodimer with 
Tango  and binds central midline elements (CME) to regulate genes that direct midline cell development 
and axon growth, such as TGF-β, FGF-receptor and Slit. 
 
     Two mammalian homologs of dsim, Sim1 and Sim2, share a high degree of similarity 
in their PAS domains, but little conservation is apparent in their carboxyl termini.  Sim1 
and Sim2 interact with ARNT and bind the CME (Fig. 4), but differ from Drosophila 
sim, the aryl hydrocarbon receptor (AHR) and hypoxia inducible factor (HIF) by 
functioning as transcriptional repressors (Moffett et al., 1997; Moffett & Pelletier, 2000).  
Mouse Sim1 and Sim2 show considerable sequence divergence from dsim over the C-
terminal region and unlike the other members of the bHLH/PAS family, do not contain 
transactivation domains and instead act as repressor proteins when heterodimerised with 
ARNT (Ema et al., 1996; Moffett et al., 1997).  Sim2-mediated repression occurs in two 
ways, through both sequestration of ARNT from other partner proteins and active 
transrepression, i.e.  the direct repression of the transactivation domain of ARNT (Ema 
et al., 1996).  A repression domain has been mapped to the C-terminus of Sim2, and 
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Sim2 repression is dependent on this domain (Moffett et al., 1997). 
 
 
Figure 4. Transcriptional regulation by Sim.   Sim interacts with ARNT and bind the CME to function 
as transcriptional repressors. 
 
 
     Sim1 and Sim2 are expressed in a variety of tissues including brain, kidney, lung and 
skeletal muscle where they play important developmental roles.  After human SIM2 was 
first identified (Chrast et al., 1997), the mouse homolog was subsequently mapped to the 
syntenic region on chromosome 16.   In addition, a splice variant of human SIM2, 
designated SIM2 short (SIM2s), has also been identified (Chrast et al., 1997) (Fig. 5).  
This splice variant, which is missing exon 11 and therefore lacks a portion of the region 
implicated in mediating the repressive effects of SIM2, is reported to be involved in 
cancer susceptibility (DeYoung et al., 2002; DeYoung et al., 2003); however, functional 
differences between these two isoforms have not been reported.   
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Figure 5. Comparison of Drosophila, human and mouse single minded genes. 
 
 
     Since the bHLH-PAS proteins share structural motifs and common binding partners, 
it is not surprising that cross-talk can occur between PAS-protein mediated pathways.  
The relationship among bHLH-PAS proteins is depicted in Figure 6. 
 
 
Figure 6. Array of Arnt interactions.  The diagram shows the different proteins that Arnt/Tgo interacts 
with and the developmental and physiological processes these protein complexes control.  The in vivo 
relationship between Arnt, Clock, and Per remains speculative. 
 
     In the case of the HIF proteins, both SIM1 and SIM2 can compete with HIFs for 
ARNT binding, and interact with a prototypical hypoxia response element (HRE) to 
affect gene expression (Moffett et al., 1997; Moffett & Pelletier, 2000; Woods and 
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Whitelaw, 2002).  Interestingly, SIM1/ARNT, but not SIM2/ARNT, can induce 
transcription of an HRE-controlled reporter gene via the C-terminal transactivation 
domain of ARNT (Woods and Whitelaw, 2002).  In contrast, ARNT-mediated 
transactivation of a CME-controlled reporter gene is severely impaired in the presence of 
SIM2 and is dependent upon the SIM2 dimerization domain and carboxyl terminus, 
which contains two separate repressive domains (Moffett et al., 1997; Moffett & 
Pelletier, 2000).  Since repression by SIM2 is not specific for ARNT, as SIM2-Gal4 
fusion constructs have repressive effects on a thymidine kinase promoter (Chrast et al., 
1997), it is thought that SIM2-mediated repression can also occur through direct 
interactions with the basal transcription machinery.  Similar to dSim, SIM1 and SIM2 
also bind and regulate transcription through a consensus CME, which isn't surprising 
since the CME core sequence (5'-ACGTG-3’) is identical to that of the HRE (Fig. 7).  As 
was seen for the HRE, SIM1 strongly activates transcription of a CME-controlled gene 
through the transactivation domain of ARNT, whereas SIM2 is repressive (Moffett et al., 
1997). 
 
 
Figure 7. Comparison of HRE and CME. 
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1.4. Mammary development 
     Branching morphogenesis is regulated by positive and negative factors that direct the 
migration of cells during development in numerous branching tissues and organs 
including lung, kidney, central nervous system and mammary glands.   Interactions 
between the epithelium and its surrounding stroma are the major driving force for 
induction of branching.   A problem faced by all branching organs is that of confining 
growth to a select few cells, for example those at the tips of the terminal end bud (TEB) 
in the developing mammary gland (Fig. 8).   During tumorigenesis this balance between 
the stroma and epithelium is disrupted leading to uncontrolled growth and metastasis. 
     The mammary gland is a dynamic organ the structure of which changes throughout 
the female reproductive cycle.  Development of the gland occurs in defined stages that 
are connected to sexual development and reproduction, namely embryonic, prepubertal 
and pubertal stages, pregnancy, lactation and involution.  Two cellular compartments 
constitute the gland: the epithelium and the surrounding stroma, which are derived 
embryologically from ectoderm and mesoderm respectively (Parmar & Cunha, 2004).  
Mammary gland development relies on interactions between the epithelium and stroma 
to drive cell migration and differentiation.   Disruption of the interaction between the 
epithelium and stroma can both induce and promote breast cancer.  Crosstalk between 
the mammary epithelium and stroma is also crucial for the proper patterning and 
function of the normal mammary gland.  During its developmental cycle the mammary 
gland displays many properties associated with breast cancer.  Moreover, many of the 
factors implicated in breast cancer are also vital for mammary development.  
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Understanding how these factors function in normal development may provide a better 
understanding of how tumors begin and thrive (Wiseman and Werb, 2002).   
 
 
Figure 8. The two distinct mechanisms of branching morphogenesis in the pubertal mouse 
mammary gland.  The mouse mammary gland branches through two distinct mechanisms: bifurcation of 
TEBs and side branching.  Bifurcation of TEBs to form primary and secondary branches occurs only from 
immature ducts.  The branch point is formed through deposition of stroma at the cleft site, and the ducts 
extend directly into adipose tissue, without myoepithelial cells or stroma and with only a minimal 
basement membrane at their invasive front.  In contrast, in side branching, a new branch forms from a 
mature duct.  First, the region where the bud is to form must be defined.  Then the emerging bud extrudes 
through and remodels a region containing layers of myoepithelial cells, basement membrane, and 
periductal stroma.  Distinct molecules have been implicated in each type of branching.  Factors involved in 
side branching include the progesterone receptor, Wnts, HSPGs, nuclear factor kB (NFkB), MMPs, TIMP-
1, TGFβ and its receptor ( TGFβIIR), gelsolin, P-cadherin, CCAAT/enhancer binding protein b (C/EBPβ), 
CSF-1, Stat5a, and Stat5b.  Factors involved in TEB formation include b1 integrin, laminin-1, MMPs, 
discoidin domain receptor-1 (DDR-1), GH, IGF-I and its receptor IGF-IR, Ptc-1, inhibins and activins, and 
p27Kip-1. Adapted from Wiseman & Werb, 2002. 
 
 
     Mammary gland development is unique because it mainly occurs post-embryonically 
during adolescence while most vertebrate organs are patterned during embryogenesis 
and then maintain their basic structure throughout adult life.  In the mouse, mammary 
gland development begins at approximately embryonic day 10, when the epithelium 
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grows from the nipple region into the surrounding stroma establishing a rudimentary 
mammary tree.   At puberty, ovarian hormones initiate a proliferative phase of ductal 
elongation, which is driven by the TEB (Chepko and Smith, 1999; Daniel et al., 1989; 
Muller and Neville, 2001).    
 
 
Figure 9. Mammary gland development in mice 
 
 
     The TEB is a bulb-like structure that is highly proliferative within a single "cap cell" 
layer that invades the fat pad leaving differentiated ducts behind (Silberstein, 2001).   
During pregnancy, the mammary gland undergoes expansion and terminal differentiation 
of the mammary epithelium into milk-producing lobuloalveolar structures and 
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differentiation of the large fat cells into tiny preadipocytes (Hennighausen & Robinson, 
2001).  Terminal differentiation of the alveolar epithelium is completed at the end of 
gestation with the onset of lactation.  After weaning, the entire alveolar epithelium of the 
mammary gland dies by apoptosis, the fat cells redifferentiate, and the gland is 
remodeled back to a state resembling that of the adult nulliparous mouse (Alexander et 
al., 2001).  The mammary gland development cycle is depicted in Figure 9. 
1.4.1. Stroma plays an important role in mammary gland development 
     During the mammary development, the mammary epithelium proliferates and invades 
into the stromal tissue.  However, the mammary stroma also plays an important role by 
providing the epithelial cells with both instructive and permissive signals (Wiseman & 
Werb, 2002).  The stroma consists of many cell types, including fibroblasts, adipocytes, 
endothelial cells, extracellular matrix and inflammatory cells, each subject to regulation 
throughout the entire developmental cycle.  In the embryonic stage, mouse mammary 
epithelial buds emerge from the embryonic epidermis as a result of stromal induction.  
This initial stage of mammary gland development depends on reciprocal signaling 
between epithelium and the stroma instead of systemic cues (Parmar and Cunha, 2004).  
When embryonic mammary epithelium was co-cultured with embryonic salivary 
mesenchyme, the mammary tissue developed salivary gland-like lobules (Sakakura, 
1991).  Sakakura also showed that adult mammary tissue also responded in this way to 
salivary stromal signals.  At puberty, the TEB develop on the end of the ducts, the site of 
intense DNA synthesis that elicits ductal elongation.  In addition to the terminal end 
buds, lateral buds develop along mature ducts, grow a short distance, and then stop 
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because of the presence of other competing ductal elements.  Alveolar buds develop in 
most mouse strains only in response to the hormones of pregnancy.  Postnatal mammary 
gland development and function are highly dependent upon the actions of pituitary, 
adrenal and ovarian hormones such as estrogen, progesterone, prolactin and 
corticosteroids (Parmar & Cunha, 2004).   
 
Table 4.  In vivo murine mammary morphogens. Adapted from Fata et al., 2004. 
Morphogen Branching* Mode of application 
Extracellular factors   
Estrogen ↑ Administered 
Estrogen ↑ Slow-release pellet 
Anti-estrogen ↓ Slow-release pellet 
Progesterone ↓ Slow-release pellet 
Parathyroid-hormone-related peptide ↓ Homozygous deletion 
Parathyroid-hormone-related peptide ↓ Transgenic overexpression 
Parathyroid hormone ↓ Transgenic overexpression 
Corticosterone ↓ Administered 
Epidermal growth factor (EGF) ↑ Slow-release pellet 
TGF-β1 ↓ Slow-release pellet 
TGF-β2 ↓ Slow-release pellet 
TGF-β3 ↓ Slow-release pellet 
Insulin-like growth factor 1 ↓ Homozygous deletion 
Growth hormone ↑ Slow-release pellet 
Hepatocyte growth factor ↑ Transgenic overexpression 
Relaxin ↑ Systemically administered 
Amphiregulin ↑ Overexpressing transplants 
Amphiregulin ↑ Slow-release pellet 
Hereguln-α ↑ Slow-release pellet 
Heregulin-β ↑ Slow-release pellet 
Wnt-4 ↓ Homozygous deletion 
Wnt-4 ↑ Overexpressing transplants 
C-neu ↓ Transgenic overexpression 
Colony-stimulating factor ↓ Homozygous deletion 
Eotaxin ↓ Homozygous deletion 
MMP-3 (stromelysin-1) ↑ Transgenic overexpression 
TIMP-1 ↑ Transgenic antisense TIMP-1 
TIMP-1 ↓ Slow-release pellet 
Receptors   
EGF receptor (EGFR) ↓ Homozygous deletion 
Epidermal-growth-factor receptor ↑ Transgenic/dominant negative 
Estrogen receptor α ↓ Homozygous deletion 
Progesterone receptor A (PRA) ↑ Transgenic overexpression 
Progresterone receptor A/B ↓ Homozygous deletion 
Prolactin receptor ↓ Homozygous deletion 
TGF-β2 receptor ↑ Transgenic/dominant negative 
Intracellular factors   
CCAAT/enhancer binding protein β ↓ Homozygous deletion 
Gelsolin ↓ Homozygous deletion 
Hox6C ↓ Homozygous deletion 
* ↑, augmentation of branching; ↓, inhibition of branching.  MMP, matrix metalloproteinase; TGF, 
transforming growth factor; TIMP, tissue inhibitor of metalloproteinase. 
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     Two mechanistically distinct processes, TEB bifurcation and sprouting of side 
branches from mature ducts, in mammary gland branching are depicted in Figure 8.  
During TEB bifurcation, the distal epithelial cells abut the fat cells through a sparse 
basement membrane, and stromal matrix is deposited to form a cleft at the site of 
bifurcation.  In contrast, side branches must extend through the layer of myoepithelial 
cells, degrade the basement membrane that surrounds the mature epithelial ducts, and 
invade a periductal layer of fibrous stromal tissue that separates the epithelium from the 
fat cells of the mammary fat pad (Wiseman & Werb, 2002) (Fig. 8).  A number of 
paracrine, juxtacrine, and autocrine factors are known to affect mammary gland 
branching morphogenesis and summarized in Table 4 (Fata et al., 2004). 
1.4.2. The ECM and stromal factors in mammary branching and tumorigenesis 
     Interaction between the epithelium and the extracellular matrix (ECM) plays a major 
role in mammary gland branching morphogenesis.  Mammary gland branching 
morphogenesis is dependent, in part, on the ECM, ECM receptors, such as integrins, and 
ECM-degrading enzymes, including matrix metalloproteinases (MMPs) and their 
inhibitors, tissue inhibitors of metalloproteinases (TIMPs).  There is some evidence that 
these ECM cues affect one or more of the following processes: cell survival, polarity, 
proliferation, differentiation, adhesion, and migration (Fata et al., 2004).  Direct 
attachment of epithelial cells to ECM occurs through basally located integrins (Table 5) 
and nonintegrin ECM receptors (Table 6). 
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Table 5.  Integrin heterodimers and their corresponding ECM ligands. Adapted from Fata et al., 2004. 
Integrin ECM ligands 
α1β1 Laminins, collagens 
α2β1 Laminins, collagens, tenascin 
α3β1 Laminins, collagens, fibronectin, entactin 
α4β1 Fibronectin, osteopontin 
α5β1 Fibronectin, tenascin 
α6β1 Laminins 
α7β1 Laminins 
α8β1 Fibronectin, tenascin, vitronectin 
α9β1 Collagen type I, laminin, tenascin, osteopontin 
αVβ1 Vitronectin, fibronectin, osteopontin 
α2β1 Collagen type I 
αIIbβ3 Fibronectin, vitronectin, thrombospondin 
αVβ3 
Vitronectin, fibronectin, osteopontin, entactin, thrombospondin, denatured collagens, tenascin, 
laminin 
α6β4 Laminins 
αVβ5 Vitronectin, osteopontin, fibronectin 
αVβ6 Fibronectin 
αVβ7 Fibronectin 
αVβ8 Fibronectin, vitronectin 
 
 
 
Table 6.  Nonintegrins implicated in branching morphogenesis. Adapted from Fata et al., 2004. 
Nonintegrin ECM ligands 
β-1,4-glactosyltransferase N-acetylglucosamine residues 
Dystroglycan Laminin 1 
Discoidin domain receptor 1 (DDR1) Collagens 
Galectin Laminin, fibronectin, vitronectin, N-acetylglucosamine residues 
 
 
      TEB formation and ductal invasion requires ECM factors, such as discoidin domain 
receptor–1, which can serve as a collagen receptor, β1 integrin, which recognizes many 
ECM proteins, the ECM protein laminin-1, and several matrix metalloproteinases 
(MMPs), which cleave ECM and other proteins in the cellular microenvironment.  
Specific MMPs refine the mammary branching pattern by distinct mechanisms during 
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mammary branching morphogenesis.  Wiseman et al.  (2003) proposed that MMP2 and 3 
regulates mammary gland branching in different phases (Fig. 10).   
 
 
Figure 10. Model for different phases of mammary gland branching morphogenesis.  Before puberty, 
the mammary epithelial is small and simply branched.  In response to the release of estrogen (E) and 
growth hormone (GH), at 3 wk old TEBs form.  MMP-2 is then involved in inducing TEBs to invade and 
the ducts begin to fill the fat pad by branching dichotomously through bifurcation.  At 6–8 wk old, the 
mammary ducts branch laterally.  This process is suppressed by MMP-2 and induced by MMP-3 and may 
be related to changes in the response of the gland to progesterone (P) and prolactin (PRL).  The fat pad is 
filled with ducts at 10 wk old and is relatively quiescent until pregnancy, when there is another wave of 
lateral branching that is regulated by MMP-3, P, and PRL before the formation of lobular alveoli. Adapted 
from Wiseman et al., 2003. 
 
 
     DDR1-deficient mice have excessive mammary collagen deposition, delayed ductal 
development, enlarged terminal end buds, hyperproliferative ducts, and incomplete 
lactational differentiation (Vogel et al., 2001).  Blocking β1 integrin or the γ1 chain of 
laminin induced terminal end bud regression, fewer terminal end buds, and decreased 
ductal elongation in developing mammary glands (Klinowska et al., 1999).  MT1-MMP 
cleaved laminin-5 to release bioactive laminin fragments that induce the migration of 
breast epithelial cells (Koshikawa et al., 2000).   Proper side branching also requires that 
the ECM and the cellular microenvironment surrounding the ductal epithelium be 
maintained.  Unrestrained side branching often results in tumorigenesis.  Indeed, 
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overexpression of MMP-3, MMP-14, Wnt-1 induced excessive side branching and 
eventual tumorigenesis in the mouse mammary gland.  In contrast, a reduction in side 
branching occurs in mice deficient in MMP-3 and Wnt-4 (Wiseman & Werb, 2002).  Liu 
and colleagues (2003) proposed that TCF-dependent transactivational activity is 
suppressed in 50% of cells in Sydecan-1 knockout glands, and conclude that the major 
effect of Sdc1 does not map to the activity of the Wnt signaling complex, but to another 
pathway to create or stabilize the b-catenin/TCF-responsive tumor precursor cells in 
mouse mammary gland.  Transforming growth factor-β1 (TGF-β1) influences mammary 
gland development by altering the composition of the ECM.  Localized release of TGF-
β1 from a pellet implanted in the stromal compartment induced intense collagen I gene 
expression (Silberstein et al., 1990).  Transforming growth factor-ß1 also positively 
regulates expression of ECM proteins such as fibronectin, collagen IV, and laminin in 
human mammary epithelial cells (Stampfer et al., 1993).  The virgin P-cadherin–null 
female mice displayed precocious differentiation of the mammary gland and the P-
cadherin mutant mice develop hyperplasia and dysplasia of the mammary epithelium 
with age (Radice et al., 1997). 
1.4.3. Stromal regulation of involution 
     After weaning, the gland goes through a process of death and remodeling termed 
involution, which is initiated by milk stasis once milk removal has ceased (Quarrie et al., 
1996).  During involution, 90% of the epithelium dies by apoptosis and fat cells replace 
that tissue.  There are three stages of involution.  The first stage of involution is triggered 
by local factors related to milk accumulation rather than changes in systemic hormone 
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levels.  When suckling is interrupted, the first need of the mother is to, at least 
temporarily, reduce milk production.  However, these changes are reversible if suckling 
is resumed within 48 hrs.  This provides a mechanism for both the mother and her 
offspring to survive short separations.  In this stage, individual mammary epithelial cells 
die by apoptosis, but the general structure of the mammary gland is maintained (Furth et 
al., 1997).  This stage is regulated locally by milk stasis, is dependent on the tumor 
suppressor gene p53 (Wiseman & Werb, 2002).  If suckling is not resumed, then the 
irreversible second stage of involution begins.  This stage is characterized by decreased 
systemic hormone levels and proteinase activation.  Irreversible tissue remodelling 
follows with near complete loss of the epithelial cell compartment (Furth et al., 1997).  
The second stage is also characterized by apoptosis, but this is mediated by lactogenic 
hormones and is independent of p53.  This stage is irreversible and is dependent on 
proteinases.  The third stage is a biosynthetic phase in which the mammary stroma is 
remodeled and repopulated with adipogenic cells (Wiseman & Werb, 2002).   
     In the first stage of involution, apoptosis is inhibited by the transcription factors 
Stat5a and interferon regulatory factor–1 (IRF-1) and promoted by the transcription 
factor Stat3 and the growth factor TGF-β3.  Stat3 may induce apoptosis by inducing a 
known promoter of apoptosis, IGF binding protein–5 (IGFBP-5), and by down-
regulating Stat5a (Wiseman & Werb, 2002).   
     During the second stage of involution, apoptosis likely occurs because the epithelial 
cells lose their adhesion to a basement membrane, which is destroyed by the increased 
proteinase activity.  As a result, the cells lose survival signals from the ECM (Wiseman 
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& Werb, 2002).  The expression of TIMPs is downregulated around day 3 of involution 
with the concomitant upregulation of MMPs and serine proteinases such as stromelysin-
1, stromelysin-3, gelatinase A and urokinase-type plasminogen activator (Marti et al., 
1999).   
     Involution of the mammary gland can be achieved more quickly in a situation of 
reduced proteinase activity.  TIMP-1 overexpressing mice or MMP-3 deficient mice 
showed an accelerated involution which was due to an increase in adipogenesis rather 
than an alteration in apoptosis (Alexander et al., 2001). 
1.4.4. Development of the human mammary gland 
     It will be meaningful to take a closer look at human mammary development.  Parmar 
and Cunha (2004) presented a profound description on the development of the human 
mammary gland in their recent review.  The first visible indication of human mammary 
gland development can be found during day 35 (4th week), with the proliferation of 
paired areas of epithelial cells in the epidermis of the thoracic region.  Subsequently, 
these areas of proliferation extend in a line between the fetal axilla and inguinal region 
and form two indistinct ridges called the mammary ridges or milk streaks.  By the end of 
week 6, the mammary ridges have regressed back to two areas in the thoracic region, 
where two solid epithelial masses (the mammary buds) begin to grow downwards into 
the underlying mesenchyme (Fig. 11).  This solid core of cells continues to evaginate 
into the underlying mesenchyme and becomes surrounded by a more cellular zone of 
fibroblast-like cells within a dense collagenous stroma.  The 9th week is the cone stage, 
at which there is further inward growth of the mammary placode.  Between the 10th and 
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12th weeks, called the budding stage, epithelial buds sprout from the invading placode, 
and the buds become lobular in shape, with notching (indentation) of the epithelial–
stromal border.  In the epidermis overlying the developing gland, the nipple begins to 
form.  During the same period, the mesenchymal cells differentiate into fibroblasts, 
smooth muscle cells, capillary endothelial cells and adipocytes.  Further branching into 
15–25 solid epithelial cords marks the branching stage at 15 weeks.   
                                  
 
        
Figure 11. Schematic drawing of embryonic human breast development.  A. Early epidermal 
mammary ridge.  B. From the mammary ridge, solid epithelial sprouts grow into underlying mesenchyme 
to form lactiferous ducts. Adapted from Parmar and Cunha, 2004. 
 
 
     Around week 20, the solid mammary cords canalize, and the epidermis in the region 
of the nipple becomes depressed, forming the mammary pit.  The epithelial cells lining 
the ducts first appear as a bilayer of cuboidal cells.  The luminal layer rapidly acquires 
the characteristics of secretory cells, whereas the basal layer becomes myoepithelial.  By 
A 
B 
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6 months of gestation, the basic tubular architecture of the fetal gland has become 
established.  In contrast to rodent development, glands develop similarly in both the 
female and male human fetuses (Howard & Gusterson 2000). 
     After birth, the mammary gland becomes quiescent until the onset of puberty in girls, 
when it resumes growth of both the glandular tissue and the surrounding stroma.  The 
ducts elongate, branch and form club-shaped terminal end buds, as seen in the mouse.  
The terminal end buds give rise to new branches and small ducts or alveolar buds 
(Parmar & Cunha, 2004).  As in the fetus, from birth to puberty there are no identifiable 
morphological differences in the development of the breasts in boys and girls (Howard 
& Gusterson 2000). 
     At puberty, changes occur in both the epithelium and stroma.  In the stroma, there is 
an increase in the amount of fibrous and fatty tissue, with the adult non-lactating breast 
consisting of 80% or more of stroma.  Indeed, the extension of ducts in the pubertal 
human breast is preceded by proliferation of connective tissue; fatty tissue is believed to 
inhibit growth of human breast epithelium (Howard & Gusterson 2000).  Small bundles 
of primary and secondary ducts grow, divide, and form club-shaped terminal end buds.  
Terminal end buds give origin to new branches, twigs, and small ductules or alveolar 
buds.  Alveolar buds cluster around a terminal duct, forming the lobule type 1 or virginal 
lobule (Fig. 12) and each cluster is composed of approximately 11 alveolar buds.  
Lobule formation in the female breast occurs within 1–2 years after onset of the first 
menstrual period.  Full differentiation of the mammary gland is a gradual process taking 
many years, and in some cases, if pregnancy does not supervene, is never attained 
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(Russo & Russo, 2004). 
 
 
Figure 12. Diagrammatic representation of the lobular structures of the human breast. Adapted from 
Russo and Russo, 2004. 
 
 
     The lobules have been classified as types 1, 2, 3 and 4 lobules (Russo & Russo 1987).  
In type 1 (virginal lobule), alveolar buds cluster around a terminal duct.  Terminal ducts 
or alveolar buds are lined by a bi-layered epithelium, whereas four layers of epithelial 
cells line terminal end buds.  The transition from lobule type 1 to type 2 to type 3 is a 
gradual process of sprouting of new alveolar buds.  In type 2 and type 3 lobules, ductules 
increase in number from about 11 per type 1 lobule to 47 and 80 ductules per type 2 and 
type 3 lobules respectively.  Type 1 lobules are mainly found in the breast of nulliparous 
young women, whereas lobules type 2 and type 3 are more frequent in the gland of 
parous women.  Type 4 lobules are the maximal expression of development and 
differentiation in the adult gland, seen in pregnancy when glands are secreting milk and 
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have undergone complete functional differentiation (Figs. 12 & 13). 
     During pregnancy, the breast attains its maximum development; it occurs in two 
distinctly dominant phases characteristic of the early and late states of pregnancy.  The 
early stage is characterized by growth consisting of proliferation of the distal elements of 
the ductal tree, resulting in the formation of ductules that at this stage, can be called acini, 
thus developing a lobule type 3 into a lobule type 4.  The intensity of budding and 
degree of lobule formation goes beyond what has been observed in the virginal breast 
(Russo & Russo, 2004). 
 
 
 
Figure 13. Drawings depicting the functional development of the human breast, the basic functional 
unit of which is the terminal ductal–lobular unit (TDLU).   A. Diagram of a TDLU emerging from the 
extralobular terminal duct (ETD).  B. Diagram depicting the histology of a normal TDLU in the resting 
nulliparous state, showing the terminal duct and associated acini.  C. Drawing of terminal branching 
structures from a 15-year-old human breast.  An extralobular duct is shown with rudimentary terminal 
branching structures.  True lobules and acini are not yet present.  D. Drawing of TDLUs from a 22-yearold 
nulliparous human mammary gland having well developed lobules and acini.  E. Drawing of breast 
structures of a 30-year old pregnant woman.  Note well developed TDLUs.  F. Drawing of breast tissue of 
a 55-year-old parous menopausal woman.  Ducts are dilated, and the TDLUs are atrophied.  G. Drawing of 
breast tissue of a 80-year-old woman.  Marked atrophy of ducts and TDLUs can be seen. Adapted from 
Parmar and Cunha, 2004. 
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1.5.  Breast cancer 
     In the United States, breast cancer is the most frequently diagnosed cancer among 
women with an estimated 211,240 invasive breast cancer diagnoses in 2005.  It is second 
only to lung cancer as a cause of cancer death among women and over 40,000 women 
will die from breast cancer each year in the United States.  It was estimated that about 
58,490 carcinomas in situ of the breast and 46,170 melanoma in situ would be newly 
diagnosed in 2005 (Jemal et al., 2005).       
 
 
Figure 14. Anatomy of female breast. Adapted from Osborne, 2000. 
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     The breasts lie over the pectoral muscles which attach them by a layer of connective 
tissue known as the fascia.  The mammary gland is supported by two layers of Cooper’s 
ligaments.   These arise from stromal elements in the gland and insert into the skin and 
pectoral fascia, holding the breast against the chest.  The breast is made up of the 
secretory glandular tissue and surrounding adipose tissue (Fig. 14).   
     The glandular tissue comprises between 15 and 20 lobes separated by septa of 
connective tissue.  Each lobe has its own duct system and connects to a lactiferous duct, 
several of which converge to form a lactiferous sinus.  These sinuses empty into the 
nipple where there are a number of duct openings.  Each lobe has a lactiferous duct so 
there are a series of openings in the nipple.  Each lobe consists of many lobules; hence 
the main lactiferous ducts give rise to many branches, the intralobular ducts.  The nipple 
is surrounded by a pigmented area, the areola, which is lubricated by secretions from the 
sebaceous glands (Osborne, 2000). 
     Breast cancer refers to the uncontrolled growth and proliferation of cells that 
originate in the breast tissue and there are several types of tumors that may develop 
within different areas of the breast.  Some cancers are called in situ because cancer cells 
are confined to the ducts and do not invade surrounding fatty and connective tissues of 
the breast.  They are also called ‘noninvasive’.  Ductal carcinoma in situ (DCIS) is the 
most common form of non-invasive breast cancer (90%).   Lobular carcinoma in situ 
(LCIS) is less common and many physicians do not classify LCIS as breast cancer.  
Other cancerous breast tumors are invasive or infiltrating.  In this case, cancer cells 
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break through the duct and lobular wall and invade the surrounding fatty and connective 
tissues of the breast.   Cancer can be invasive without being metastatic to the lymph 
nodes or other organs.  Infiltrating lobular carcinoma (ILC) or invasive lobular 
carcinoma begins in the lobules of the breast, but often spreads to other regions of the 
body.  ILC accounts for 10% to 15% of breast cancers.  Infiltrating ductal carcinoma 
(IDC) or invasive ductal carcinoma begins in the ducts of the breast and penetrates the 
wall of the duct, invading the fatty tissue of the breast and possibly other regions of the 
body.  IDC is the most common type of breast cancer, accounting for 80% of breast 
cancer diagnoses (Hoehne & Taylor E, 2005).  Although less common, there are several 
other types of breast cancers: medullary carcinoma, mucinous carcinoma, tubular 
carcinoma, inflammatory breast cancer, Paget’s disease of the nipple, and phylloides 
tumor (Hoehne & Taylor E, 2005). 
1.5.1. Risk factors for breast cancer 
     Although the exact cause of breast cancer is unknown, it has been found that women 
with certain risk factors are more likely to develop breast cancer.  A risk factor is 
anything that increases the chances that a particular disease will develop. 
Genetics: Alteration of certain genes may cause some cells to become cancerous.  It has 
been shown that 5-10% of breast cancer cases are hereditary (Lux et al., 2006).   Genetic 
diseases predisposing an individual to cancer have led to the identification of numerous 
tumor suppressor genes including BRCA-1 and -2 (familial breast cancer), PTEN 
(Cowden’s Disease), APC (familial polyposis), LKB1 (Peutz-Jeghers syndrome), WT1 
(Wilms Tumor) and P53 (Li-Fraumeni syndrome) (Groden et al.,1991; Haber et al.,1990; 
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Hemminki et al., 1998; Liaw et al., 1997; Malkin,1994; Moynahan et al., 2002).  Women 
who carry mutations of BRCA1 (breast cancer gene 1) or BRCA2 (breast cancer gene 2) 
are at higher risk of developing both breast and ovarian cancer than women who do not 
have these genetic mutations (Moynahan, 2002).  Currently, women with BRCA1 
mutations account for 5% of all breast cancer cases.  Jewish women of Northeastern 
European decent (Ashkenazie women) have a higher prevalence of BRCA1.  Human 
epidermal growth factor receptor 2(HER2) also plays a key role in regulating cell growth.  
The over-expression of HER2 causes increased cell growth and reproduction, often 
resulting in more aggressive tumor cells.  HER2 protein over-expression affects over 
20% of breast cancer patients (Martin, 2006).  Germline p53 mutations have been 
identified in patients with Li-Fraumeni cancer susceptibility syndrome, an autosomal 
dominant disorder.  It is characterized by a markedly increased risk of breast cancer with 
early-onset (Malkin, 1994).   
Gender: Breast cancer is the most common form of cancer among women in the United 
States, while it is uncommon in males.  One third of cancer diagnosis and 15% of cancer 
deaths are attributed to breast cancer in women (Lacey et al., 2002).  The risk of 
development of breast cancer is 100 times higher in females compared to males 
(Andersen et al., 1992).  Female breast cells are constantly exposed to the growth-
promoting effects of estrogen and progesterone, thus making breast cancer much more 
common in women than men.   
Age: The risk of developing breast cancer increases with age, with most breast cancers 
occurring after age 50 (Callebaut and Mornon, 1997).  About 18% of breast cancer 
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diagnoses are among women in their 40s, while about 77% of women with breast cancer 
are older than 50 when they are diagnosed.  In contrast, breast cancer incidence is less 
than 10 new cases per 100,000 women before age 25 and increases up to 100-fold by age 
45 (Hulka & Moorman, 2001). 
Race: White women are slightly more likely to develop breast cancer than are African-
American women.  But African-American women are more likely to die of this cancer.  
Asian, Hispanic, and Native American women have a lower risk of developing and 
dying from breast cancer (Dumitrescu & Cotarla, 2005).   
Geographical location: Breast cancer incidence and mortality vary considerably by 
world region.  In general, the incidence is high (greater than 80 per 100,000) in 
developed regions of the world and low (less than 30 per 100,000), though increasing, in 
developing regions; the range of mortality rates is much less (approximately 6-23 per 
100,000) because of the more favorable survival of breast cancer in (high-incidence) 
developed regions (Parkin & Fernandez, 2006).  Incidence rates are high in most of the 
developed areas (except for Japan, where it is third after colorectal and stomach cancers), 
with the highest age-standardized incidence in North America (99.4 per 100,000).  The 
incidence is more modest in Eastern Europe, South America, Southern Africa, and 
Western Asia, but it is still the most common cancer of women in these geographic 
regions.  The rates are low (<30 per 100,000) in most of Africa (with the exception of 
South Africa) and in most of Asia.  The lowest incidence is in Central Africa (ASR, 16.5 
per 100,000) (Parkin et al., 2005).  The large variation of breast cancer incidence among 
or within different regions of the world may be attributed to genetic differences among 
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populations and/or differences in lifestyle, including diet and environmental exposures.  
Interestingly, breast cancer incidence increases in people who move from a region with 
low breast cancer incidence to other locations with higher breast cancer incidence.  John 
et al.  (2005) reported that breast cancer risk was 50% lower in foreign-born Hispanics 
than U.S.-born Hispanics.  They also found that risk increased with increasing duration 
of residence in the United States, decreasing age at migration, and increasing 
acculturation.  Migrants from urban areas had a risk 30% higher than migrants from rural 
areas.  Migrants who had lived in the West for a decade or longer had a risk 80% higher 
than more recent migrants (Ziegler et al., 1993).  These imply the crucial contribution of 
the environmental and sociocultural factors to breast cancer risk.   
Reproductive factors: Reproductive hormones have been shown to play a critical role 
in breast cancer etiology in many epidemiologic data, animal models, and in vitro studies.  
Lifetime exposure to endogenous sex hormones is determined by several variables 
including age at menarche, age at first full-term pregnancy, number of pregnancies and 
age at menopause, which have been studied all in relation to breast cancer risk 
(Dumitrescu & Cotarla, 2005).  Early menarche, late menopause, older age at first full-
term pregnancy, lower parity, and fewer numbers of pregnancies may increase risk of 
breast cancer by affecting the endogenous reproductive hormones (Hulka & Mooreman, 
2001).   
   Early age at menarche (less than 12 years of age) has been associated with an increase 
in breast cancer risk.  Breast cancer risk declines 10–20% with each year that menarche 
is delayed (Titus-Ernstoff et al., 1998).  Late age at menopause is also associated with 
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increased breast cancer risk.  Longer menopause represents a longer time period of 
exposure to ovulatory menstrual cycles.  Breast cancer risk is about two times greater for 
those with a last menstrual period at age 55 years or later than for those whose last 
period occurred at age 45 or younger (Bernstein, 2002).  Early pregnancy has a 
protective effect against breast cancer.  Both early age (less than 20 years versus more 
than 30 years) at first full-term pregnancy and higher parity decrease breast cancer risk 
to half of the risk of nulliparous women.  Early age at second pregnancy further reduces 
the risk of breast cancer.  In contrast, nulliparity and late age at first birth contribute 
towards an increased risk of developing breast cancer.  Interestingly, women with their 
first birth after age of 35 are even at higher risk than nulliparous women (Dumitrescu & 
Cotarla, 2005).  It also has been reported that prolonged lactation reduces the risk of 
breast cancer (Enger et al.  1998).  Beral (2002) reported a 4.3% decrease in the relative 
risk of breast cancer for every 12 months of breastfeeding, in addition to a decrease of 
7.0% for each birth.  The decrease of breast cancer risk due to prolonged lactation may 
be explained by a markedly reduced susceptibility of the fully differentiated mammary 
gland to carcinogens, by the altered hormonal environment during pregnancy, and by the 
reduction of total number of ovulatory menstrual cycles and consequently cumulative 
ovarian hormone exposure (Dumitrescu & Cotarla, 2005). 
Family history of breast cancer: Family history of breast cancer increases a woman's 
risk of developing the disease.  Collaborative Group on Hormonal Factors in Breast 
Cancer (2001) reported that 87% of breast cancers occurred in women with no affected 
first-degree relatives, 12% in women with one affected relative, and 1% in women with 
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two or more affected relatives.  About 20% to 30% of women with breast cancer have a 
family member with this disease.   
Personal history of breast cancer: Women with a history of prior invasive breast 
cancer or history of noninvasive breast lesions have an increased risk for developing 
invasive breast cancer (Vokes and Golomb, 2003). 
Hormone replacement therapy: It has become clear that long-term use of hormone 
replacement therapy (HRT) after menopause, particularly estrogens and progesterone 
combined increase the risk of breast cancer (Ross et al., 2000).   
Alcohol: Many studies showed a slight increase in breast cancer risk with alcohol 
consumption.  Jain et al.  (2001) reported a slightly elevated risk when 10 g of ethanol 
were consumed.  Breast cancer risk is higher for women consuming moderate to high 
levels of alcohol (3 drinks/day) compared with abstainers, and that there is a significant 
dose-response relationship beginning with intakes as low as 1 to 2 drinks per day.  The 
proportion of breast cancer cases among US women that can be attributed to alcohol 
intake has been estimated to be as low as 2%, but the proportion is as high as 15% in 
Italy, where the average alcohol intake is higher (Singletary & Gapstur, 2001).  A great 
number of epidemiological studies have clearly identified chronic alcohol consumption 
even in moderate amounts as a risk factor for breast cancer.  84% of the 69 case–control 
and 76% of the 21 cohort studies published so far show a positive association between 
ethanol intake and breast cancer.  So have all six meta-analyses to date.  It was 
calculated that 4% of all newly diagnosed breast cancer cases in the US are primarily 
due to alcohol (Poschl & Seitz, 2004).  It has been demonstrated that postmenopausal 
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women who have a higher-alcohol and low-folate intake have an increased risk for 
developing estrogen receptor-negative tumors (Sellers et al., 2002). 
Obesity: Obesity has been found to be a breast cancer risk in all studies, especially for 
women after menopause (Adderley-Kelly & Williams-Stephens, 2003; McTiernan et al., 
2003).  Weight gain during adult life has been associated with increased risk of 
postmenopausal, but not premenopausal, breast cancer (Huang et al., 1997; Magnusson 
et al., 1998).   Huang et al.  (1997) have also showed a stronger association between 
obesity and postmenopausal breast cancer risk in women who have never used hormone 
replacement therapy.  Postmenopausal obesity increases the risk for developing breast 
cancer due to higher levels of endogenous estrogen, because adipose tissue is a primary 
source of circulating estrogens in postmenopausal women (McTiernan et al., 2003).   
Other risk factors: There are many other breast cancer risk factors such as history of 
breast benign diseases, mammographic density, bone density, prolactin, diet, previous 
radiation, smoke, physical activity and so on (Dumitrescu & Cotarla, 2005). 
 
1.6. Connection between mammary development and breast cancer 
     The developing mammary gland displays many of the properties associated with 
tumor progression, such as invasion, reinitiation of cell proliferation, resistance to 
apoptosis, and angiogenesis.  The TEB invades into stromal tissue as a solid tumor does.  
Furthermore, the epithelium must retain the ability to initiate proliferation throughout its 
lifetime.  The lactating mammary gland protects it from premature involution, actively 
resisting apoptotic signals.  In addition, as the mammary gland needs the blood supply to 
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be adjusted, the mammary gland induces angiogenic remodeling as tumors do.  As the 
mammary gland retains many of these properties throughout its lifetime, many of the 
factors essential for mammary gland development are also associated with cancer.  In the 
mammary gland, a variety of genes have been implicated in the developmental processes, 
and many of these genes have also been linked to tumorigenesis (Wiseman and Werb, 
2002). 
 
1.7. Tumor suppressor genes 
     Tumor suppressor genes refer to those genes whose loss of function results in the 
promotion of malignancy.  Tumor suppressor genes are usually negative regulators of 
growth or other functions that may affect invasive and metastatic potential, such as cell 
adhesion and regulation of protease activity (Osborne et al., 2004).  The inactivation of 
various tumor suppressor genes is important in the development and progression of 
breast cancer.  Tumor suppressor genes are considered to act mostly in a recessive 
fashion, i.e.  some abnormality must affect both gene alleles.  The classical inactivation 
of tumor suppressor genes, i.e.  the Knudson ‘Two-Hit’ hypothesis, is caused by tumor 
suppressor gene loss due to chromosomal loss of one allele, and mutation of the other 
remaining allele.  The two-hit hypothesis first proposed by Knudson predicts that loss of 
one copy of a tumor suppressor gene renders an organism more susceptible to 
tumorigenesis (Knudson et al., 2000).   Consistent with this hypothesis, haplosufficiency 
for several genes including p27, p53, Ink4a, PTEN, BRCA1 and BRCA2 has been 
shown to enhance the rate of mammary cancer (D'Amico et al., 2003; Medina et al., 
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2002; Berton et al., 2003; Muraoka et al., 2002; Kuperwasser et al., 2000; Li et al., 
2001).   
      Besides genetic alteration, the inactivation of tumor suppressor genes can be result 
from nongenetic (or epigenetic) mechanisms, including hypermethylation (Foster et al.  
1998), increased degradation (Storey et al.  1998), mislocalization (Chen et al.  1995), or 
abnormalities in other proteins that interact with the gene product. 
     Tumor suppressor genes have various mechanism of action.   Some tumor suppressor 
genes, such as Rb or INK family of cdk inhibitors, are directly involved in controlling 
proliferation by regulating cell cycle checkpoints.  The retinoblastoma (Rb) gene was the 
first tumor suppressor to be discovered.  In breast cancer, mutation or loss of Rb is 
present in up to 30% of cases, and it has been associated with a greater likelihood of 
progression (Andersen et al., 1992). 
     In contrast, certain tumor suppressor genes have an indirect effect on growth.  They 
are responsible for genome integrity, and changes in such genes lead to genome 
instability.  For example, The ATM gene senses DNA damage and activates checkpoints 
and DNA repair pathways.  Loss of both alleles of the ATM gene causes ataxia-
telangiectasia, a syndrome of progressive cerebellar degeneration, blood vessel fragility, 
immunological defects, and predisposition to lymphoid malignancies (Shiloh, 2003). 
     Tumor suppressor genes are also are involved in epithelial-stromal and epithelial-
epithelial interactions.  E-cadherin is a major mammary epithelial cell-cell adhesion 
molecule and loss of E-cadherin function contributes to breast cancer progression by 
promoting cell proliferation, invasion and metastasis (Hu et al., 2003). 
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1.8. Epithelial-mesenchymal transitions 
     Polarized epithelial cells are converted into motile mesenchymal cells during 
embryonic development and in tumor progression.  Epithelial-mesenchymal transitions 
(EMTs) occur as key steps during embryonic morphogenesis in many animal species.  
This process is very important of early development.  In vertebrates it facilitates the 
formation of a three-layered embryo by gastrulation.  EMT has also been implicated in 
the ontogeny of other structures including heart endocardium, musculoskeletal system, 
most craniofacial structures and the peripheral nervous system (Thiery, 2002).   The 
development of the mammary gland probably employs these mechanisms.  EMT is one 
of the most drastic aspects of epithelial cell plasticity.  Some of the molecular programs 
of EMT might be involved in the development of the mammary gland, particularly at 
terminal end buds or possibly in lateral branching.  However, EMT is also likely to be 
important in tumor progression.  Increasing evidence suggests that EMT plays a specific 
role in the migration of cells from a primary tumor into the circulation.   
     One of the best markers of EMT associated with breast cancer is the loss of E-
cadherin, and this is controlled in part by Snail family members, as is EMT associated 
with development (Vincent-Salomon and Thiery, 2003).  Cadherins are essential for the 
development and maintenance of mammary luminal epithelial cells.  Adhesion between 
vertebrate cells is generally mediated by three types of adhesion junction: ‘tight 
junctions (TJs)’, ‘adherens junctions (AJs)’, and desmosomes.  Cadherins are the 
principal components of AJs and desmosomes, and cluster at sites of cell–cell contact in 
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most solid tissues (Cavallaro & Christofori, 2004) (Fig. 15).   
 
 
Figure 15. Three types of adhesion junctions and EMT. 
    
     Epithelial(E)-cadherin is a major mammary epithelial cell-cell adhesion molecule and 
has been implicated as an important signaling component in maintaining normal growth 
and differentiation (Delmas et al., 1999; Boussadia et al., 2002; Stockinger et al., 2001).   
Cellular polarity and inhibition of migration are promoted and controlled by E-cadherin-
containing adherens junctions, and loss of E-cadherin is an early step in EMT (Berx et 
al., 1996; Nathke et al., 1994; Berx et al., 1995; Savagner et al., 1997).   E-cadherin 
mediated adhesion is regulated, in part, by β-catenin, which couples it to the actin 
cytoskeleton (Nathke et al., 1994).   In addition to determining cell fate, cadherin-catenin 
complexes stabilize mammary gland architecture, dictate epithelial cell polarity, promote 
survival and inhibit motility.   E-cadherin is the prototypic type I cadherin.  Type I 
cadherins mediate homophilic interactions by forming adhesive bonds between one or 
several immunoglobulin (Ig) domains in their extracellular region and connecting to 
actin microfilaments indirectly via α-catenin and β-catenin in the cytoplasm.  The de 
novo production of E-cadherin in normal and transformed mesenchymal cells can induce 
the formation of stable cell–cell contacts and the development of AJ.  In epithelial cells, 
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early contacts are also mediated by E-cadherin molecules that cluster into small 
junctional complexes, which then expand to establish stable AJ and promote the 
formation of desmosomes.  E-cadherin is required for the maintenance of stable 
junctions: anti-E-cadherin antibodies can disrupt these contacts and induce a 
mesenchymal phenotype (Thiery, 2002).  Inactivation of E-cadherin is associated with 
invasive breast cancer, premature apoptosis and involution in mice.   Consequently, 
expression of a stabilized β-catenin in the mouse mammary gland causes precocious 
alveolar development, hyperplasia, delayed involution and mammary tumors (Imbert et 
al., 2001).  Wnt/β-catenin singaling pathway is also involved in EMT (Fig. 16).  Non-
sequestered, free α-catenin and β-catenin are rapidly phosphorylated by glycogen 
synthase kinase 3 (GSK-3) in the adenomatous polyposis coli (APC)–axin–GSK-3 
complex and are subsequently degraded by the ubiquitin–proteasome pathway.  If the 
tumour suppressor APC is non-functional, as in many colon cancer cells, or if GSK-3 
activity is blocked by the activated WNT-signalling pathway, β-catenin accumulates at 
high levels in the cytoplasm.  Subsequently, it translocates to the nucleus, where it binds 
to members of the TCF/LEF1 family of transcription factors and modulates the 
expression of their target genes, including c-MYC, cyclin D1, fibronectin, MMP7, ID2, 
CD44, NrCAM, axin-2, TCF1 and others, which are mostly genes implicated in cell 
proliferation and tumour progression.  The loss of E-cadherin function would 
subsequently lead to the activation of the WNT signalling pathway.  In various cellular 
systems, sequestration of β-catenin by E-cadherin can compete with the β-catenin/TCF-
mediated transcriptional activity of the canonical WNT signalling pathway (Cavallaro & 
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Christofori, 2004). 
     EMT can be induced in several epithelial cell lines by growth factors activating 
tyrosine kinase surface receptors, which include hepatocyte growth factor, fibroblast 
growth factors, epithelial growth factor (EGF) family members, and insulin-like growth 
factors 1 and 2 (Thiery, 2002).  Although the transient activation of Src, 
phosphoinositide 3-kinase (PI3K) and Rac has an effect on particular aspects of EMT in 
some cell lines, the Ras/mitogen-activated protein kinase (MAPK) pathway has a crucial 
role in inducing EMT in the most cases.  TGF-β is a potent inducer of EMT in co-
operation with the Ras pathway (Janda et al., 2002).  MAPK and PI3K have also been 
implicated in TGF-β signaling and more direct signalling, both through the conventional 
Smad pathways and other as yet unknown pathways.  The classical TGF-β signaling 
pathway leading to inhibition of cell growth or even the induction of apoptosis is 
abrogated by activated Ras in part through Raf/MAPK or PI3K activation.  In addition, it 
has been clearly shown in the skin carcinogenesis model that nuclear accumulation of 
Smad2 by oncogenic Ras is required for progression towards the spindle cell carcinoma 
stage (Vincent-Salomon and Thiery, 2003).  Snail or Slug, a closely related member of 
the Snail superfamily, control gastrulation and neural-crest EMT.  They control EMT by 
repressing E-cadherin expression in breast cancer (Cano et al., 2000; Hajra et al., 2002).  
Similarly, Twist, a bHLH transcription factor, represses E-cadherin to cause EMT 
(Thiery & Morgan).  EMT can also be induced by ECM components, including 
collagens and laminin 5 (Grassi et al., 1999).  Stromelysin 1 (matrix metalloprotease 
[MMP]-3) also induces EMT in vitro and tumorigenesis in vivo (Sternlicht et al., 1999).  
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Figure 17 shows the possible signaling pathway involving E-cadherin and other factors. 
 
 
 
 
Figure 16. Potential signalling pathways affected by loss of E-cadherin function.  After loss of 
epithelial (E)-cadherin function and disassembly of the cytoplasmic cell-adhesion complex (CCC), 
catenins are released and accumulate in the cytoplasm.  β-Catenin (β) is then sequestered by the 
adenomatous polyposis coli (APC)–axin–glycogen synthase kinase 3 (GSK-3) complex and 
phosphorylated by GSK-3.  Phosphorylated β-catenin is specifically bound by TrCP, a subunit of the E3 
ubiquitin-ligase complex.  However, on activation of the WNT signalling pathway, GSK-3 is repressed 
and β-catenin is no longer phosphorylated.  It translocates to the nucleus where, together with the 
TCF/LEF1 transcription factors, it modulates the expression of several target genes that are known to be 
involved in cell proliferation and tumour progression. Adapted from Cavallaro & Christofori, 2004 
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Figure 17. Signaling pathways involving E-cadherin. 
 
 
1.9. Matrix metalloproteases 
           The mammary gland is composed of two compartments: epithelium and stroma 
which are separated by the basement membrane.  Therefore, tissue remodeling requires 
degradation of the basement membrane and surrounding extracellular matrix.   This 
occurs during normal mammary gland development, and under pathological conditions 
such as tumor progression and metastasis (Andarawewa et al., 2003; Alexander et al., 
2001; Ha et al., 2001; Lee et al., 2000).   To establish metastatic growth, cancer cells 
must pass through the basement membranes at least three times (Fig. 18).  Breast cancer 
cells initially cross these membranes when an in situ carcinoma becomes an invasive 
lesion.  Later, malignant cells transverse these structures during both entry into and exit 
from the blood stream (Duffy et al., 2000).  Figure 18 depicts the process in detail. 
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     Normal epithelia lined by a basement membrane can proliferate locally to give rise to 
an adenoma.  Further transformation by epigenetic changes and genetic alterations leads 
to a carcinoma in situ, still outlined by an intact basement membrane.  Further alterations 
can induce local dissemination of carcinoma cells, possibly through an EMT, and the 
basement membrane becomes fragmented.  The cells can intravasate into lymph or blood 
vessels, allowing their passive transport to distant organs.  At secondary sites, solitary 
carcinoma cells can extravasate and either remain solitary or they can form a new 
carcinoma through a mesenchymal-epithelial transition (Thiery, 2002).   
 
 
Figure 18. Process of EMT and MET in the emergence and progression of carcinoma. Adapted from 
Thiery, 2002. 
 
     MMPs play a critical role in this process by actively degrading ECM components.  
The MMPs are endopeptidases that can cleave virtually any component of the ECM.   
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There are eight distinct structural classes of MMPs: five are secreted and three are 
membrane-type MMPs (MT-MMPs) (Fig. 19).   
 
 
 
Figure 19. The protein structure of the MMPs.  Secreted MMPs: The minimal-domain MMPs contain 
an amino-terminal signal sequence (Pre) that directs them to the endoplasmic reticulum, a propeptide (Pro) 
with a zinc-interacting thiol (SH) group that maintains them as inactive zymogens and a catalytic domain 
with a zinc-binding site (Zn).  In addition to the domains that are found in the minimal domain MMPs, the 
simple hemopexin-domain-containing MMPs have a hemopexin-like domain - that is connected to the 
catalytic domain by a hinge (H) - which mediates interactions with tissue inhibitors of metalloproteinases, 
cell-surface molecules and proteolytic substrates.  The first and the last of the four repeats in the 
hemopexin-like domain are linked by a disulphide bond (S–S).  The gelatin-binding MMPs contain inserts 
that resemble collagen-binding type II repeats of fibronectin (Fi).  The furin-activated secreted MMPs 
contain a recognition motif for intracellular furin-like serine proteinases (Fu) between their propeptide and 
catalytic domains that allows intracellular activation by these proteinases.  This motif is also found in the 
vitronectin-like insert (Vn) MMPs and the membrane-type MMPs (MT-MMPs).  MT-MMPs: MT-MMPs 
include transmembrane MMPs that have a carboxy-terminal, single-span transmembrane domain (TM) 
and a very short cytoplasmic domain (Cy), and the glycosylphosphatidylinositol (GPI)-anchored MMPs.  
MMP-23 represents a third type of membrane-linked MMP.  It has an N-terminal signal anchor (SA) that 
targets it to the cell membrane, and so is a type II transmembrane MMP.  MMP-23 is also characterized by 
its unique cysteine array (CA) and immunoglobulin (Ig)-like domains. Adapted from  Egeblad and Werb, 
2002. 
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     Secreted MMPs, the minimal-domain MMPs, contain an amino-terminal signal 
sequence that directs them to the endoplasmic reticulum, a propeptide with a zinc-
interacting thiol group that maintains them as inactive zymogens and a catalytic domain 
with a zinc-binding site.  In addition to the domains that are found in the minimal 
domain MMPs, the simple hemopexin-domain-containing MMPs have a hemopexin-like 
domain - that is connected to the catalytic domain by a hinge - which mediates 
interactions with tissue inhibitors of metalloproteinases, cell-surface molecules and 
proteolytic substrates.  The first and the last of the four repeats in the hemopexin-like 
domain are linked by a disulphide bond.  The gelatin-binding MMPs contain inserts that 
resemble collagen-binding type II repeats of fibronectin.  The furin-activated secreted 
MMPs contain a recognition motif for intracellular furin-like serine proteinases between 
their propeptide and catalytic domains that allows intracellular activation by these 
proteinases.  This motif is also found in the vitronectin-like insert MMPs and the 
membrane-type MMPs (MT-MMPs).  MT-MMPs include transmembrane MMPs that 
have a carboxy-terminal, single-span transmembrane domain and a very short 
cytoplasmic domain, and the glycosylphosphatidyl-inositol-anchored MMPs.  MMP-23 
represents a third type of membrane-linked MMP.  It has an N-terminal signal anchor 
that targets it to the cell membrane, and so is a type II transmembrane MMP.  MMP-23 
is also characterized by its unique cysteine array and immunoglobulin-like domains 
(Egeblad and Werb, 2002). 
1.9.1. MMPs are involved in breast cancer initiation and growth 
     Batimastat, a synthetic inhibitor of MMPs, inhibited tumor formation and metastasis 
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in a nude mouse injected with MDA-MB-435 breast cancer cells (Sledge et al., 1995).  
Overexpression of MMP3 in transgenic mice gave rise to preneoplastic and malignant 
mammary gland tumors (Wiesen and Werb, 1996).  Transgenic mice expressing 
matrilysin under the control of mouse mammary tumour virus (MMTV-long terminal 
repeat promoter/enhancer) developed premalignant hyperplastic nodules.  Mating 
MMTV-matrilysin mice with MMTV-neu transgenic mice resulted in offspring that 
developed primary mammary tumors about 13 weeks earlier than MMTV-neu controls 
(Rudolph-Owen et al., 1998).   
     Cancer initiation or to tumor cell growth by MMPs may be involved with increased 
angiogenesis, activation of stimulating growth factors or their receptors, and inactivation 
of inhibiting growth factors.  Angiogenesis, the recruitment of new blood vessels, is an 
essential component of the metastatic pathway.  These vessels provide the principal 
route by which tumor cells exit the primary tumor site and enter the circulation (Zetter, 
1998).  The process begins with local degradation of the basement membranes that 
surround capillaries, followed by invasion of the surrounding stroma by the underlying 
endothelial cells in the direction of the angiogenic signal.  Endothelial cell migration is 
accomplished by cell growth at the leading edge of the migrating column.  The 
endothelial cells then organize themselves into three-dimensional structures to form new 
capillary tubes (Duffy et al., 2000).  MMPs degrade the extracellular matrix and thereby 
allowing endothelial cell invasion; and liberate factors that promote or maintain the 
angiogenic phenotype.  For example, MMP2 enhances mammary epithelial growth by 
the degradation of the ECM protein laminin-5.  Both MMP-1 and MMP-3 release basic 
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FGF to breakdown endothelial-derived perlecan (Stetler-Stevenenson, 1999). 
     Cancer initiation or to tumor cell growth by MMPs is involved with increased 
activation of stimulating growth factors or their receptors.  MMP inhibitors were shown 
to reduce cell proliferation in direct proportion to their effect on transforming growth 
factor-α release (Dong et al., 1999).  MMP-1 was shown to specifically degrade insulin-
like growth factor (IGF) binding proteins 2, 3 and 5, fibroblast growth factor (FGF) 
binding protein and transforming growth factor (TGF)-β binding protein and release IGF, 
FGF and TGF-β (Vu & Web, 2000).  Matrix metalloproteinase 2 releases active soluble 
ectodomain of fibroblast growth factor receptor 1.  Because the hydrolyzed ectodomain 
retains its ability to bind FGF, it has the potential to modulate the mitogenic and 
angiogenic activities of FGF (Levi et al., 1996).  IGFs are released when IGF-BPs are 
cleaved by MMP9 (Manes et al, 1999).   
1.9.2. MMPs are also strongly related with invasion and metastasis 
     MMPs are strongly associated with cancer-cell invasion and metastasis.  Reduction of 
MT1-MMP from MDA-MB-231 breast cancer cell resulted in significant reduction of in 
vitro invasiveness and loss of response to an invasion stimulus, HGF (Jiang et al., 2006).  
Batimistat reduced spontaneous metastasis of a highly malignant rat mammary cancer 
(Eccles et al., 1996).  When MMP3 is overexpressed in transgenic mice the mammary 
gland undergoes precocious involution and is predisposed to forming a reactive stroma 
resembling that of a wound site or a tumor (Wiesen et al.  1996).  E-cadherin is cleaved 
by MMP3 or MMP7 and the released fragment of E-cadherin promotes tumour-cell 
invasion (Noe et al., 2001) 
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    The MMPs are synthesized as inactive zymogens (pro-MMPs).  They are kept inactive 
by an interaction between a cysteine-sulphydryl group in the propeptide domain and the 
zinc ion bound to the catalytic domain: activation requires proteolytic removal of the 
propeptide prodomain.  Most of the MMPs are activated outside the cell by other 
activated MMPs or serine proteinases (Egeblad & Werb, 2002).  The ratio of active to 
latent form of MMP-2 increased with tumour progression in invasive breast cancers 
(Davies et al., 1997) 
 
1.10. Research objectives 
     Single minded-2, a member of the bHLH-PAS family of proteins, plays a key role in 
the developing central nervous system (CNS) by regulating a number of genes that guide 
neuron growth.  SIM2 was initially identified by positional cloning on chromosome 21 
and contributes to many of the physiological abnormalities associated with DS as a result 
of trisomy-21.   Sim2 is also expressed in a number of branching organs including the 
lung, kidney and mammary gland; however, its function in these tissues has not been 
determined.  The pattern of occurrence of malignant disorders in people with DS is 
unique with a very high risk of leukemia in childhood extending into young adulthood 
and a decrease in the risk of solid tumors at all ages.   Women experience a lower risk 
than men, mainly due to the absence of breast cancer and this may be a result of a gene 
dosage effect of tumor suppressor genes on chromosome 21.   Although SIM2 is 
associated with critical biological functions, very little is known regarding its role in 
development outside of the CNS, and even less is known about its role in cancer 
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susceptibility. 
1.10.1. Objective 1 
     In Drosophila, Single minded acts as the master regulator of central nervous system 
midline development by controlling expression of many genes required for 
differentiation.  Drosophila sim forms a heterodimer with ARNT and bind CME in the 
regulatory regions of target genes to activate expression of proteins required for proper 
central midline establishment.  In mammalian, SIM interact with ARNT, but differ from 
Drosophila sim, the AHR and HIF by functioning as transcriptional repressors.  In 
mouse, Sim1 and Sim2 are expressed in a variety of tissues including brain, kidney, lung 
and skeletal muscle where they play important developmental roles.  After hSIM2 was 
first identified, the mouse homolog was subsequently mapped to the syntenic region on 
chromosome 16.   In addition, SIM2s has also been identified.  This splice variant lacks 
a portion of the region implicated in mediating the repressive effects of SIM2.  However, 
functional differences between these two isoforms have not been reported.  Thus, 
differential transcriptional regulation of Sim2s will be intensively studied by isolating 
mouse Sim2s homolog and characterizing its expression profile and transcriptional 
properties.   
1.10.2. Objective 2 
     In Drosophila, the central midline of the developing CNS serves a number of critical 
functions by providing signals to guide the path of growing axons and regulate epidermis 
development.  dsim serves as a master regulator of Drosophila midline differentiation by 
controlling all steps of midline development.   Drosophila CNS midline cell regulation 
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of axon branching and development is dependent upon dsim regulation of genes 
involved in cell fate determination and stromal-epithelial interactions.  Transgenic mice 
over-expressing Sim2 display many of the mental characteristics seen in DS individuals 
including learning impairment and reduced fear response, implying that Sim2 plays a 
key role in many of the physiological phenotypes seen in DS.  Thus, the working 
hypothesis is that Sim2s plays a crucial role in determining and/or maintaining 
mammary epithelial cell fate and function.   We will characterize the overall role of 
Sim2s, using C57Bl/6J mice and Sim2 knock-out mice. 
1.10.3. Objective 3 
     Individuals with DS are more than 50% less likely to develop solid tumors including 
cancers of the lung, colon, skin, head and neck.   Especially, women with DS are 10-25 times 
less likely to develop breast cancer in comparison to age-matched normal populations.  Women 
with DS rarely become pregnant, increasing their risk for breast cancer; however, they 
experience earlier menopause, leading to a decrease in risk.   Thus, hormonal factors alone are 
unlikely to explain the significantly decreased rate of breast cancer and protective factors are 
more likely to be genetically linked.  Based on the facts, we hypothesized that SIM2 is a breast 
cancer suppressor gene.  This will be tested by reestablishing SIM2s into MDA-MB-435, a 
highly invasive breast cancer cell line.  This study will also provide valuable insights into 
possible mechanisms of SIM2s tumor suppressor activity. 
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II. MATERIALS AND METHODS* 
 
2.1. Animals   
     C57Bl/6J, Sim2-/-, and athymic nude mice were housed under standard 12 hr lights 
on/off conditions in a temperature and humidity controlled facility with food and water 
provided ad libitum.  All animal housing and treatments were approved by and 
conformed to the Animal Use Protocols at Texas A&M University.   
 
2.2. Cell lines    
     The cell lines used in these studies were obtained from American Type Culture 
Collection (ATCC).   The 16N normal breast epithelial cells and 21T breast cancer cells 
were a gift from Dr.  Heide Ford at the University of Colorado Health Science Center 
and were grown as previously described (Coletta et al., 2004).   HEK-293T and HepG2 
cells were cultured in DMEM (Life Technologies, Gaithersburg, MD) containing 10% 
FBS and 1% Penicillin-streptomycin.  HEK-293t Ampho-Phoenix packaging cells were 
obtained from ATCC with permission from Dr.  Gary Nolan at Stanford University and 
maintained as recommended.   All cells were grown in 5% CO2 at 37°C.   
 
2.3. RNA isolation and reverse transcription  
     Total RNA was initially isolated from mouse tissues using Trizol reagent (Invitrogen 
                                                 
* Parts of this section are reprinted from Metz et al., 2006, J Biol Chem, 281(16), 10839-10848, Copyright 
© 2006 by the American Society for Biochemistry and Molecular Biology and Kwak et al., 2006, 
Carcinogenesis, in progress, Copyright © 2006 by Oxford University Press. 
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Carlsbad, CA) and was further purified using RNeasy kits (Qiagen, Valencia, CA) with 
on-column DNase digestion (Qiagen).  One microgram of total RNA was reverse 
transcribed using oligo dT and Superscript II reverse transcriptase (Invitrogen). 
 
2.4. 3’ Rapid Amplification of cDNA Ends (RACE)  
     Total RNA (2 µg) was reverse transcribed using an oligo-dT-based adapter primer 
(AP-dT17) (5’-GAT CAG GAC GTT CGT TTG AGT TTT TTT TTT TTT TTT T-3’).  
An initial round of PCR was performed using 1ul of a 1:100 dilution of the RT reactions 
with the adapter primer (AP) (5’-GAT CAG GAC GTT CGT TTG AGT-3’) and a Sim2-
specific primer located in exon 9 (P1; 5’-AGT CCC AGG AGT CCT GGA-3’).  
Subsequent rounds of PCR were performed on 1ul of a 1:100 dilution of the previous 
reaction using the adapter primer and nested Sim2 primers (P2; 5’-AAA TCA GCT 
AAA CCC AAA AAC ACA AA-3’, P3; 5’-AG AAC CAA CCC ATA TCC CC-3’ P4; 
5’-CTT CTC CTG TGA ATG CTG C-3’).  The PCR products were cloned into pCR II-
TOPO (Invitrogen), and screened for inserts by restriction enzyme analyses.  Clones 
positive for the insert were sequenced (DNA Technologies Lab, Texas A&M University) 
and compared to the reported mouse Sim2 and chromosome 16 sequences.  The 
sequence of the Sim2s 3-RACE product was submitted to GenBank and was assigned 
the accession number AY963781. 
 
2.5. RT and real-time PCR   
     Total RNA was isolated using RNeasy Mini kits (Qiagen, Valencia, CA) along with 
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the RNase-free DNase Set (Qiagen, Valencia, CA) to remove genomic DNA.   One µg 
total RNA was reverse transcribed into cDNA using oligo (dT) and Superscript II 
reverse transcriptase (Invitrogen, Carlsbad, CA).  PCR reactions contained 1µl cDNA 
template with 1µM each primer, 0.4mM dNTPs and 1 unit Taq DNA Polymerase 
(Promega, Madison, WI) per 25µl reaction.  Primers used were: Sim1 (FP; 5’-GGT CAG 
CCA GTG AAT CTG GT-3’, RP; 5’- TGG TCT CCT GCT GTC TGA TG -3’), Sim2s 
(FP; 5’- AAA TCA GCT AAA CCC AAA AAC ACA AAG ATG-3’, RP; 5’- TCC CTG 
TGA GGT CAC GAA TA -3’), Sim2 (FP; 5’- AAA TCA GCT AAA CCC AAA AAC 
ACA AAG ATG -3’, RP; 5’- TAG TGG CCG CAG CTC GGG AA -3’, Total (pan) 
SIM2 (FP: 5’-TGA AAT GTG TCT TGG CGA AAA-3’, RP: 5’-GCG TAG CGG AGG 
TGG AAC-3’), SIM2s (FP: 5’-GCT GAG AAC AAA CCC TTA CC-3', RP: 5’-GAA 
GCA GAA AGA GGG CAA GTT-3’), SIM2L (FP: 5’-CAG GTT CGG CGA GGA 
CAC-3’, RP: 5’-ACC TCC CGT TGG TGA TGA T-3’) and GAPDH (FP: 5’-AAT CCC 
ATC ACC ATC TTC CA-3’, RP: 5’-GTC ATC ATA TTT GGC AGG TT-3’).   Real 
time PCR was performed using SYBR Green Master Mix (Applied Biosystems, Foster 
City, CA).   Primers for analyzing total SIM2 by real time PCR were FP: 5’- AGA CAA 
AGC TGA GAA CAA ACC CTT A -3’ and RP: 5’- CCG CAT TCC AGT TTG TCC 
AT -3’.   MMP3 was analyzed using the primers FP: 5’- TTC CTG ATG TTG GTC 
ACT TCA GA -3’ and RP: 5’- TCC TGT ATG TAA GGT GGG TTT TCC -3’.   TBP 
was used as a normalizing gene and was assayed using the primers FP: 5’- TGC ACA 
GGA GCC AAG AGT GAA -3’ and RP: 5’- CAC ATC ACA GCT CCC CAC CA -3’.   
Product specificity was determined by dissociation curve analyses after each run and 
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product identities were confirmed by sequencing.   Real time PCR data were analyzed by 
the ∆∆CT method (Hettinger et al., 2001).   The relative positions of the SIM2-specific 
primers used are indicated in Fig. 20A.   
 
2.6. Plasmid construction 
     The full-length mouse Sim2s plasmid (pcDNA-mSim2s) was made by amplifying the 
5’ most 1548-bp of Sim2 from pmSim2-GAL4-HA (kindly provided by Dr.  Jerry 
Pelletier, McGill University, Montreal, Quebec, Canada) using HiFi Taq DNA 
polymerase (Roche, Indianapolis, IN) and the primers 5’-ATG AAG GAG AAG TCC 
AAA AAT GC-3’ and 5’-AGC ATT CAC AGG AGA AGG CTC AGA A-3’.  This 
fragment was cloned into pCR II-TOPO, and the 5’ Spe I fragment was cut out and 
ligated to Spe I/Xba I cut pCRmSim2s-8 (original Sim2s 3’RACE clone) to create 
pCRFLmSim2s.  After the sequence was confirmed, the entire insert was removed by 
EcoR I digestion, and cloned into EcoR I-cut pcDNA3.  pmSim1-HA and pmSim2-HA 
were a kind gift of Dr.  Jerry Pelletier.  Full-length Sim2L was removed from pmSim2-
GAL4-HA by EcoR I digestion and cloned into Eco RI-cut vectors.  Full-length ARNT 
and ARNT2 were amplified from mouse kidney and cloned into pCR II-TOPO.  Once 
the sequences were verified, the inserts were removed and cloned into pGBK-T7 and 
pGADT7-Rec. 
 
2.7. Reporter plasmids 
     pDRE-TATA-luc, pGL2-TATA and pß-gal were kindly provided by Dr.  Stephen 
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Safe at Texas A&M University (College Station, TX, USA) (Morrow et al., 2004).  
pHRE-TATA-luc was constructed by cloning annealed oligonucleotides corresponding 
to the top and bottom strands of the hypoxia-responsive region of the EPO promoter into 
pGL2-TATA (Chun et al., 2001).  pCME-luc was a kind gift of Dr.  Jerry Pelletier.  
pLNCX2-SIM2s was made by subcloning SIM2s cDNA into the EcoRI site of the 
pLNCX2 retroviral expression vector (Clontech).   pCDNA3-SIM2s was made by 
cloning the entire SIM2s insert into the EcoRI site of pcDNA3.1.   The insert from the 
largest human MMP3-luc construct (-2264 to +37) was amplified from human genomic 
DNA using the primers 5'-CCT GTT TGA CAT TTG CTA TG-3' and 5'-TTG TCT CTA 
TGC CTT GCT G-3' and cloned into pCR-2.1 TOPO (Invitrogen).   The entire insert 
was removed and cloned into pGL3-Basic.   Deletions were made by removing portions 
of -2264 MMP3-luc by restriction enzyme digest (Spe I for -1575 to +37 and EcoRI for -
275 to +37) and re-ligating the plasmids.   Oligonucleotides corresponding to three 
adjacent AP-1 consensus sites (top strand 5'-CGC TTG ATG AGT CAG CCG GAA 
CGC TTG ATG AGT CAG CCG GAA CGC TTG ATG AGT CAG CCG GAA -3') 
were synthesized, annealed and ligated into pGL2-TATA, which is described above. 
 
2.8. Co-immunoprecipitation 
     Full-length ARNT, ARNT2, Sim2 and Sim2s were made from pcDNA3-based 
expression plasmids using an in vitro translation kit (Promega).  Sim2 and Sim2s were 
made in the presence of [35S] Methionine (Amersham).  Five µl of ARNT or ARNT2 
product were mixed with 15µl radiolabeled Sim2 or Sim2s and allowed to incubate at 
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RT for 2 hr.  Five µg anti-ARNT (Upstate), anti-ARNT2 (Santa Cruz Biotechnology, 
Inc.), or rabbit IgG (Upstate) were added, and volumes increased to 150µl with water 
and 2× Co-IP buffer to make a 1Xsolution [10mM Tris-HCl (pH 7.4), 150mM NaCl, 
1mM EDTA, 1mM EGTA, 1% Triton X-100 and 0.5% Igepal].  Following 2 hr 
incubation at RT, 20µl of agarose A bead slurry was added and samples were incubated 
at RT for 1.5 hr with gently mixing.  Beads were recovered at 5000 rpm for 1 min, and 
washed 3 times in 500µl 1× Co-IP buffer.  Final pellets were resuspended in loading 
buffer, boiled and separated on polyacrylamide gels.  Gels were vacuum-dried and 
exposed to film for one week. 
 
2.9. Transient transfection 
     Sim2 and Sim2s expression was confirmed by Western analyses before large-scale 
experiments were conducted.  For each transfection, cells were seeded at 4×104 cells per 
well in 24-well plates the day before transfection.  The following morning, 200 ng 
appropriate reporter plasmid was cotransfected with 100 ng internal control (pß-Gal) and 
various amounts of test plasmids using Lipofecamine and Plus reagent (Invitrogen).  
Twenty-four hrs later, cells were incubated under hypoxic (1% O2) or normoxic (21% 
O2) conditions (pHRE-TATA-luc transfected HEK-293T cells) or in the presence of 
vehicle (DMSO) or 10 nM 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) (pDRE-TATA-
luc transfected HepG2 cells) for 40 hr.  For MMP3 reporter assays, MDA-MB-435 cells 
were added to 12-well plates (1×105 cells per well) 24 hr before transfection.   Plasmids 
(0.45 µg hMMP3-luc, 0.15 µg pcDNA3 or pcDNA3-hSim2sHA and 0.2µg ß-Gal 
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expression vector) were transiently transfected using a combination of Lipofectamine 
(2µl) and Lipofectamine Plus (5µl) reagents (Invitrogen).   Following a 24 hr recovery 
period, fresh media containing DMSO or PMA (50 ng/ml) was added.  Cells were 
harvested, and the luciferase and ß-galactosidease activities of the cell lysates 
determined by dual luciferase assay using Luciferin (Molecular probes) and Galacto-
Light (Tropix, Applied Biosystems).  Luciferase activities were normalized to the 
internal control values and are represented as the means ± S.E.  for three wells per 
condition.  Significant differences were determined using Student’s t test. 
 
2.10. Retroviral transduction 
     For retroviral transduction, SIM2s cloned into the pLNCX2 vector (Clontech), was 
transfected into Phoenix packaging cells for 6-8 hrs with 25 µl of lipofectamine and Plus 
reagents (Invitrogen).    The medium was replaced 24 hrs later and virus-containing 
supernatants were collected after 48 hrs.   Supernatants were filtered through a 0.45 µm 
filter syringe and added to MDA-MB-435 cells in 6 well plates in the presence of 8 
µg/ml polybrene (Sigma).   The plates were then centrifuged at 1000 × g at room 
temperature for 45 min.   Following a 24 hr incubation, the medium was replaced and 
stable transduced cells were selected in the presence of puromycin.   The cells were used 
within the first 10-12 passages and critical experiments were performed within the first 
few passages.   At least three independent infections were utilized and obtained similar 
results.   SIM2s expression was confirmed by RT-PCR, real time RT-PCR and 
immunofluorescence.   
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2.11. Chromatin immunoprecipitation assay 
     Twenty-four hr after transfection, formalin (270 µl per 10 ml medium) was added to 
cells and allowed to incubate at 37°C for 10 min.  Crosslinking was stopped by addition 
of glycine to a final concentration of 125 mM.  Following a series of PBS washes, cells 
were scraped and recovered by centrifugation.  Cells (500,00 cells per ChIP assay) were 
resuspended in SDS lysis buffer (50 mM Tris-HCl, pH 8.1, 1% SDS, 10 mM EDTA) and 
sonicated on ice.  Chromatin was recovered, and mixed with ChIP dilution buffer (16.7 
mM Tris-HCl, pH 8.1, 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl) 
containing 1× Complete Protease Inhibitor Cocktail (Roche).  Chromatin was cleared 
twice by incubation with agarose bead slurry at 4°C for 30 min. followed by 
centrifugation.  Antibody was added (10µg for Sim2, or C-Jun, 1µg for IgG) and 
incubated at 4°C overnight with mixing.  Agarose bead slurry was added and reactions 
were incubated at 4°C for 1 hr with mixing.  The agarose beads were recovered and 
washed successively for 5 min at 4°C in low salt (20 mM Tris-HCl, pH 8.1, 150 mM 
NaCl, 0.1% SDS, 1% Triton X-100, 2 mM EDTA), high salt (20 mM Tris-HCl, pH 8.1, 
500 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM EDTA).  LiCl (10 mM Tris-HCl, pH 
8.1, 250 mM LiCl, 1% IGEPAL-CA630, 1% deoxycholic acid, 1 mM EDTA) and TE 
(10 mM Tris-HCl, pH 8.0, 1 mM EDTA) buffers.  Chromatin was eluted at RT by 
incubation in freshly prepared elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min.  
Samples were then treated with RNase A in the presence of 200 mM NaCl and 
crosslinking reversed by incubation at 65°C for 4 hrs.  Chromatin was ethanol 
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precipitated and resuspended in buffer containing 40 mM Tris-HCl, pH 8.1, 10 mM 
EDTA and 200µg/ml proteinase K.  DNA was purified using Qiaquick PCR purification 
columns (Qiagen, La Jolla, CA) and eluted in 50 µl sterile water.  PCR detection of 
pGL2-CME immunoprecipitation targets was performed in 25 µl reactions containing 2 
µl chromatin and the primers pGL2-ChIP-F1 (5’-CCC CCT GAA CCT GAA ACA TA-
3’) and pGL2-ChIP-R1 (5’-GCC TTA TGC AGT TGC TCT CC-3’).  Thermocycling 
was done with an initial denaturation at 95°C for 5 min followed by 27 cycles of 95°C 
for 30 sec, 50°C for 30 sec, and 72°C for 30 sec followed by a final elongation step at 
72°C for 5 min.  The JUN antibody was obtained from Santa Cruz (catalog number sc-
44) 
 
2.12. Immunostaining, immunofluorescence and western blot 
     The following primary antibodies were used: anti-SIM2 (Chemicon, catalog number 
AB4145) and anti-SIM2s (Santa Cruz, catalog number sc-8715).   Secondary antibodies 
were: FITC anti–rabbit; and Texas red anti–rabbit (Molecular Probes).   Human breast 
and breast tumor tissue arrays were purchased from Chemicon (Temecula, CA).   The 
sections were baked at 55oC for 15 min then dehydrated by sequential washes in xylene 
and a series of graded ethanol washes.  Antigen retrieval was performed for 20 min at 
98°C in 0.01 mol/L sodium citrate buffer, pH 6.4, in a microwave oven.   For 
immunostaining, sections were incubated in 0.3% hydrogen peroxide for 30 min to block 
endogenous peroxidase activity.   After 30 min block in 5% milk, the sections were 
incubated with 1:100 dilution of primary antibody 1 hr at room temperature.  The 
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sections were washed in phosphate-buffered saline containing 0.1 % tween-20 and then 
incubated with either biotinylated donkey anti-goat (Vector Laboratories, Burlingame, 
CA) followed by avidin peroxidase using the Vectastain ABC elite kit (Vector 
Laboratories, Burlingame, CA) or Alexa-conjugated secondary (Molecular Probes).  The 
chromogenic reaction was carried out with 3–3' diaminobenzidine (Sigma).   The slides 
were mounted using Permount (Sigma) or Vectashield containing DAPI (Vector 
Laboratories) and evaluated under a microscope.   
 
2.13. Zymography 
     To determine MMP2 and MMP3 activity, conditioned medium from treated cells was 
concentrated ~20-fold using Centricon 10 spin concentrators (Amicon).   Samples were 
quantitated by Bradford analysis and equal amounts of protein were mixed with 
Laemmli sample buffer without reducing agents, incubated for 15 min at 37°C, and 
separated on precast gradient SDS-polyacrylamide slab gels (Invitrogen) containing 1 
mg/ml gelatin for MMP2 or casein for MMP3.  Following electrophoresis, gels were 
placed in 2.5% Triton X-100 for 30 min then incubated at 37°C in 50 mM Tris-HCl, pH 
7.4, containing 5 mM CaCl2 for 18 hrs.   MMP2 or MMP3 activity was visualized by 
Coomassie blue staining.   A non-specific band at 77 Kd was used as a loading control.   
 
2.14. Flow cytometry analysis 
     Control or SIM2s-transduced MDA-MB-435 cells were collected for cell cycle 
analysis, washed once with PBS, suspended in 500 µl of cold (–20°C) ethanol for at least 
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1 hr at 4°C, washed twice with PBS, and treated for 1 hr at room temperature with 
ribonuclease A (RNase A, 100 µg/ml) and propidium iodide (PI, 50 µg/ml).  RNase A 
and PI were from Sigma-Aldrich.  Cell cycle analysis was carried out with an EPICS XL 
2 (Beckman-Coulter).  PI binding was measured by using the FL2 photomultiplier tube 
(bandpass 575 nm) with events discriminated on forward and side scatter to exclude 
debris.  The flow rate was set at about 300 cells per second, and at least 2 × 104 cells 
were analyzed from each sample. 
 
2.15. Soft agar and invasion 
     Control or SIM2s-transduced MDA-MB-435 cells (5×103 cells per plate) in 2 ml of 
medium (DMEM + 10% FBS) supplemented with 0.35% agarose were layered onto a 
1.5-ml base of medium containing 0.5% agarose in 35-mm dishes.   Media was changed 
daily and after 14 days of growth, cells were stained with 0.005% crystal violet, 
photographed and colonies >200µm were counted.   Data presented are the summary of 
three separate experiments.   For cell invasion assays, 1 × 105 cells in 0.5 ml of serum-
free DMEM were plated in Boyden chambers containing 8 µm pore membranes coated 
with Matrigel (Becton Dickinson).   The lower chamber contained 10% FBS in DMEM 
to serve as a chemoattractant.   Following a 24 hr incubation, cells that had not left the 
top chamber were removed from the membrane by scraping.   Cells that had migrated to 
the bottom surface of the membrane were stained with Diff-Quik reagent (American 
Scientific Products, McGaw Park, IL) and examined under a bright-field microscope.  
Values are the average number of cells per 5 fields per membrane and analyzed by 
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Students t test. 
 
2.16. Transplantation 
     Mammary tissues from 1 day-old pups were dissected out under a microscope and 
transferred into the number four cleared fat pad of nude mice.  Pups for this experiment 
were obtained by mating Sim2+/- male and female mice.  During the surgery, the tails of 
pups were collected and used later for genotyping.  The transplanted glands were 
examined at 8 weeks after the transplantation.    
 
2.17. Staining 
     For whole mount staining, mammary glands were fixed in 10% neutral-buffered 
formalin overnight.   Tissues were washed three times for 1 hr in acetone, then for 1 hr 
each in 100% ethanol and 95% ethanol.   Glands were then stained for 3 hr in a solution 
of 95% ethanol, pH 1.25, containing 2.5mM FeCl3 and 0.09% hematoxylin.   Whole 
mounts were then washed twice for 1 hr in tap water, then in increasing concentrations 
of ethanol for 1 hr each (50, 70, 95 and 100%) and a final 1 hr rinse was performed in 
xylene.   H&E and trichrome staining was performed by the Veterinary Anatomy and 
Public Health Histology Core Facility at Texas A&M University.     
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III.  RESULTS* 
 
3.1. Differential transcriptional regulation by mSim2s 
3.1.1. Cloning of mSim2s 
     Previous studies have identified a splice variant of human SIM2; however, a similar 
isoform has not been reported in mice, nor have functional differences between SIM2 
and SIM2s been reported.  In order to better characterize biochemical and physiological 
differences between Sim2 and Sim2s in mice, we set out to identify the mouse Sim2s 
transcript.  Total RNA from mouse kidney and liver tissues were used for 3’RACE 
experiments since Sim2 is expressed at high levels in the kidney, but not in liver.  A 
unique adapter primer (AP-dT17) was used to reverse transcribe total RNA from the 
tissues.  This reaction was then used as a template for PCR using a primer directed to the 
AP region of the 3’ adapter and a Sim2-specific forward primer (P1, Fig. 20A).  
Subsequent PCR reactions were performed on diluted PCR products using the adapter 
primer (AP) and nested Sim2-specific primers (P2-P4, Fig. 20A).  The resulting PCR 
products from each reaction were submitted to restriction enzyme analyses for predicted 
sites to support the identity of the PCR products as Sim2 (Fig. 20B).  Potential Sim2 
clones with predicted restriction digest products were only obtained in kidney, and were 
too small to be full length Sim2.  In humans, the SIM2s splice variant is missing exon 11, 
and contains an extension of exon 10 (Chrast et al., 1997).  Based on the sequence of 
                                                 
* Parts of this section are reprinted from Metz et al., 2006, J Biol Chem, 281(16), 10839-10848, Copyright 
© 2006 by the American Society for Biochemistry and Molecular Biology and Kwak et al., 2006, 
Carcinogenesis, in progress, Copyright © 2006 by Oxford University Press. 
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mouse chromosome 16 near the region of mouse Sim2 exon 10, a single Hae III site is 
predicted to be present in the Sim2s transcript.  This was confirmed in the fourth round 
3’ RACE PCR product (Fig. 20B, right panel) suggesting that this clone is the mouse 
homolog of human SIM2s. 3’ RACE clones were sequenced and compared to reported 
mouse Sim2 sequences and chromosome 16.   
 
 
Figure 20. Isolation of mouse Sim2s by 3’ rapid amplification of cDNA ends (3’ RACE).  A. Structure 
of mouse Sim2 and Sim2s cDNAs.  Numbered squares indicate exons.  Numbered arrows indicate relative 
positions of mouse Sim2-specific primers used in 3’ RACE PCR reactions.  Dotted lines indicate relative 
positions of restriction sites used to verify identity of 3’RACE products.  B. Restriction enzyme analyses 
of mouse kidney and liver 3’RACE products.  Two micrograms of total RNA from mouse kidney or liver 
was reverse transcribed using an oligo dT-based adapter primer (AP-dT17).  An initial round of PCR was 
performed on 1µl of a 1:100 dilution of the RT reaction using the adapter primer and a mouse Sim2-
specific forward primer (P1).  The products of this initial PCR reaction were not visible (data not shown).  
Subsequent PCR reactions were performed on 1µl of a 1:100 dilution of the previous reaction using the 
adapter primer and nested Sim2-specific primers (P2, P3 and P4 in Fig. 20A).  For visualization and 
confirmation of identity, 10µl of PCR product plus (+) or minus (-) restriction enzyme was analyzed on a 
1.2% agarose gel.  Mouse Sim2s 3’RACE products are predicted to have Spe I (P2/AP), Bam HI (P3/AP) 
or Hae III (P4/AP) sites.  Sim2-specific products were only detected in kidney RNA samples, and only 
Sim2s was detected. 
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Figure 21. Structure and comparison of mouse and human SIM2s coding sequences.  A. Genomic 
structure of the mouse Sim2 locus surrounding exons 9-11.  Exons are indicated by numbered boxes and 
the “s” exon is represented by a shaded box.  B. Comparison of Sim2s with Sim2 and mouse chromosome 
16.  The 3’ boundary of exon 10 is indicated by the arrow and vertical line.  Stop codons are bold and 
underlined.  The mouse Sim2 sequence used (accession number U42554) is that of Moffett et al.  (1996).  
C. Comparison of mouse and human SIM2s coding and predicted amino acid sequences.  The 3’ boundary 
of exon 10 is indicated by the arrow and vertical line.  Stop codons are bold and underlined and 
represented as asterisks in the amino acid sequences.  Regions of amino acid identity are boxed. 
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Figure 21. Continued. 
 
        Like the human form, mouse Sim2s is missing exon 11 and contains an extension of 
exon 10 (Fig. 21A).  The mRNA (Fig. 21B) is predicted to encode a protein of 579 
amino acids that is missing the last 131 amino acids and contains an additional 53 amino 
acids encoded by the “s” exon (Fig. 21C).  Mouse Sim2s still contains the Ser/Thr- and 
Pro/Ser-rich regions shown previously to harbor repressive activities, but is missing the 
Pro/Ala-rich repressor region present in full-length Sim2 (Moffett et al., 1997).  Mouse 
and human SIM2s share 86% identity at the RNA level and are 87% homologous at the 
protein level.  Interestingly, the “s” portions of mouse and human SIM2s are not as 
homologous as the rest of the gene (Fig. 21C).   The mRNA and protein sequences of 
mouse and human SIM2 from start to the end of exon 10 are 88% and 91% homologous, 
respectively.  However, the DNA and protein sequences of the extended exon 10 regions 
of mouse and human SIM2s are only 45% and 20% homologous, respectively.  Despite 
these differences, a few amino acid residues remain conserved, including 545-GGGW-
548 and 561-SASK-564. 
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3.1.2. Sim2s preferentially interacts with ARNT over ARNT2 
     Interactions between Sim2 and ARNT proteins were confirmed biochemically by 
coimmunoprecipitation.  35S-Methionine-labeled Sim2 and Sim2s proteins were mixed 
with cold ARNT or ARNT2 and complexes precipitated with antibodies directed against 
ARNT or ARNT2.  Anti-ARNT antibody was able to pull down both ARNT/Sim2 and 
ARNT/Sim2s complexes at relatively comparable levels (Fig. 22, lanes 1 and 2).  In 
contrast, anti-ARNT2 antibody was able to pull down Sim2 slightly more efficiently 
than Sim2s (Fig. 22, lanes 3 and 4).  Although IgG control samples show some ARNT 
binding (Fig. 22, lane 5), there was very little Sim2 or Sim2s pulled down by nonspecific 
binding (Fig. 22, lane 6). 
 
 
Figure 22.  Sim2s preferentially interacts with ARNT over ARNT2.  In vitro translated ARNT and 
ARNT2 Sim2s preferentially interacts with ARNT over ARNT2.  In vitro translated ARNT and ARNT2 
were mixed with radiolabeled Sim2 or Sim2s and co-immunoprecipitated using antibodies directed at 
either ARNT or ARNT2.  Anti-ARNT antibody was highly efficient at pulling down Sim2s (lane 1) and 
Sim2 (lane 2) in the presence of in vitro translated ARNT.  Similarly, anti-ARNT2 was able to pull down 
Sim2s (lane 3) and Sim2 (lane 4) in the presence of in vitro translated ARNT2, although Sim2s was not 
pulled down as well as Sim2.  IgG pulled down ARNT to a greater extent than ARNT2 (lane 5), but was 
unable to pull down either Sim2 or Sim2s (lane 6).  A diluted mixture of radiolabeled ARNT and ARNT2 
(lane 7) as well as Sim2 and Sim2s (lane 8) were ran on the gel to verify translation efficiency. 
 
3.1.3. Transcriptional activity of mouse Sim2 and Sim2s on a HRE- and DRE-
controlled reporter genes 
     Direct targets of mammalian SIM proteins have not been determined; however, 
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indirect transcriptional activities of SIM1 and SIM2 have been reported.  In those studies, 
it was found that SIM2 can inhibit the actions of other bHLH-PAS proteins through 
active repression or competition for ARNT binding (Moffett et al., 1997; Moffett & 
Pelletier, 2000; Woods & Whitelaw, 2002).  Over-expression of Sim2 blocked hypoxia-
induced expression from HRE-controlled genes by directly binding to the HRE and 
actively repressing expression of adjacent genes.  This effect was dependent upon the 
Sim2 dimerization domain and carboxyl terminus.  Sim2 can also inhibit TCDD-induced 
expression from XRE-controlled genes, but does so by competing with AHR for ARNT 
binding.  In contrast, Sim2 represses expression of a CME driven reporter, while SIM1 
can activate CME-mediated gene expression via the ARNT transactivation domain 
(Moffett & Pelletier, 2000).  To investigate if Sim2s can affect the function of other 
bHLHPAS protein-mediated pathways, we performed co-transfection assays using 
various mouse Sim and Arnt expression plasmids with HRE-, XRE- and CME-
controlled luciferase reporter constructs. 
 
 
Figure 23. Confirmation of Sim2 expression in HEK293T cells by Western blot.  HEK293T cells 
transfected with pcDNA (Con) or increasing (3, 9 and 15 ug plasmid in 100 mm plate format) amounts of 
Sim2 or Sim2sexpression plasmids were harvested and analyzed by Western blot to confirm Sim2 gene 
expression. 
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     Expression of Sim2 and Sim2s in transfected HEK293T cells was confirmed by 
Western blotting (Fig. 23).  HEK293T cells transfected with an HRE-controlled 
luciferase reporter and the pcDNA empty vector showed a significant increase in 
luciferase activity following a 40-hr incubation under hypoxic conditions (Fig. 24).  
Introduction of increasing amounts of mouse Sim2 or Sim2s significantly repressed 
hypoxia-induced reporter gene expression.  Inclusion of 100 ng mouse ARNT 
expression vector increased the response to hypoxia and slightly overcame both Sim2 
and Sim2s-mediated repression.  Addition of mouse Arnt2 expression vector did not 
alter the response to hypoxia and both Sim2 and Sim2s repressed hypoxia-induced 
expression of the HRE-controlled reporter in the presence of ARNT2.  Increasing 
amounts of Sim2 or Sim2s did not repress in a concentration-dependent manner 
suggesting that both Sim2 and Sim2s repress hypoxia-induced gene expression through 
direct interaction with the HRE and not by competing with HIF factors for ARNT 
binding. 
     Previous studies have suggested that Sim2 can interfere with AHR-mediated gene 
expression through competition with AHR for ARNT binding (Moffett et al., 1997).  To 
determine if Sim2s exerts a similar effect on AHR-mediated signaling, HepG2 cells were 
co-transfected with a DRE-controlled reported gene with various combinations of Sim2 
or Sim2s and Arnt expression plasmids.  AHR activation was accomplished by addition 
of 10nM TCDD togrowth medium 24-hr before harvest.  A robust TCDD response seen 
in pcDNA transfected cells was significantly repressed (p<0.0001) by inclusion of either 
Sim2 or Sim2s expression plasmids (Fig. 25).   
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Figure 24. Transcriptional activity of mouse Sim2 and Sim2s on HRE-controlled reporter genes.  
HEK-293T cells were transfected with ARNT or ARNT2 expression plasmids in the presence of 
increasing amounts of Sim2 or Sim2s expression plasmids plus an HRE-controlled luciferase reporter 
vector and a ß-gal expression plasmid for normalization.  The amount of each expression vector (in ng) is 
indicated under the figure.  Following 40 hr incubation under normoxic (white bars) or hypoxic (black 
bars) conditions, cell lysates were collected and analyzed for ß-gal and luciferase activities.  Data are 
expressed as the means ± SE for three plates per condition.  *Luciferase expression under hypoxic 
conditions is higher than control (p<0.002).  **Luciferase expression under hypoxic conditions is lower in 
Sim and Sim2s-transfected compared to pcDNA-transfected cells (p<0.002).  ***Luciferase expression in 
the presence of ARNT during hypoxia is less in Sim2-transfected cells than in Sim2s-transfected cells 
(p<0.01). 
 
 
 
 
Figure 25. Transcriptional activity of mouse Sim2 and Sim2s on DRE-controlled reporter genes.  
HepG2 cells were transfected with varying amounts of either ARNT or ARNT2 expression plasmids in the 
presence of increasing amounts of Sim2 or Sim2s expression plasmid plus a DRE-controlled luciferase 
reporter vector and a ß-gal expression plasmid for normalization.  The amount of each expression vector 
(in ng) is indicated under the figure.  Following 40 hr incubation with vehicle (DMSO, white bars) or 
10nM TCDD (black bars) cell lysates were collected and analyzed for ß-gal and luciferase activities.  Data 
are expressed as the means ± SE for three plates per condition.  * Higher due to TCDD treatment 
(p<0.0001).  **TCDD-induced luciferase expression in the presence of ARNT is lower in Sim2-
transfected cells than in Sim2s-transfected cells (P<0.01). 
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The degree of this repression was not significantly different between Sim2 and Sim2s; 
however, increasing amounts of ARNT attenuated the repression (p<0.01) in both Sim2 
and Sim2s-transfected cells indicating that the mechanism of this repression involves 
competition for ARNT. 
These results are consistent with previous studies (Moffett et al., 1997) and suggest that 
Sim2 and Sim2s do not differ in their ability to repress AHR-mediated gene expression, 
which occurs through direct competition for ARNT binding. 
3.1.4. Transcriptional activity of mouse Sim2 and Sim2s on a CME-controlled 
reporter gene 
     In Drosophila, SIM regulates transcription through the CME, which contains the core 
sequence 5'-ACGTG-3' also found in an HRE.  Previous studies have shown that murine 
Sim1 and Sim2, in concert with ARNT, can bind and regulate expression of a CME 
reporter construct (Moffett & Pelletier, 2000).  Sim1 activated expression of a CME-
controlled gene through the ARNT transactivation domain, whereas full-length Sim2 
was repressive.  Activation of a CME-controlled gene by Sim2 was accomplished when 
portions of the C-terminal repression domain were deleted.  Since Sim2s is missing part 
of this repressive region, we anticipated that Sim2s would be less repressive than Sim2 
on CME-mediated gene expression.  Cotransfection of HEK293 cells with a CME-
controlled reporter gene and increasing amounts of ARNT or ARNT2 had no effect on 
reporter expression (Fig. 26).  Contrary to previous reports, we found that introduction 
of Sim2 with ARNT, but not ARNT2, resulted in a slight increase in luciferase activity 
(Fig. 26).   
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Figure 26. Transcriptional activity of mouse Sim2 and Sim2s on a CME-controlled reporter gene: 
the effects of increasing ARNT and ARNT2 on mouse Sim2- and Sim2s-mediated expression of a 
CME-controlled reporter.  HEK-293T cells were transfected with increasing amounts of ARNT or 
ARNT2 expression vector in the presence of absence of Sim2 or Sim2s expression vectors plus a CME-
controlled luciferase reporter and ßgal expression plasmid.  The amount of each plasmid per transfection 
(in ng) is indicated under the figure.  Luciferase activity was increased in both Sim2 and Sim2s-transfected 
cells, but only in the presence of ARNT, and not ARNT2.  The degree of induction was higher in Sim2s-
transfected cells in comparison to Sim2 cells.  *Luciferase expression is higher in the presence of Sim and 
Sim2s in comparison to no ARNT controls (p<0.005).  **Luciferase expression is higher in Sim2s cells in 
comparison to Sim2 cells (p<0.01).   
 
 
     Co-expression of Sim2s with ARNT, but not ARNT2, resulted in significantly 
increased reporter gene expression.  This effect appears to be ARNT-dependent as 
luciferase activity increased with increasing amounts of ARNT.  This conclusion was 
further supported by experiments utilizing constant ARNT and increasing amounts of 
Sim2 expression plasmids (Fig. 27).   Although reporter gene expression increased with 
increasing amounts of Sim2 and Sim2s expression plasmids, this effect was only 
significant in cells receiving the highest amount of Sim2 and Sim2s expression plasmid.   
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Figure 27. Transcriptional activity of mouse Sim2 and Sim2s on a CME-controlled reporter gene: 
the effects of increasing amounts of mouse Sim2 or Sim2s on CME-mediated gene expression.  HEK-
293T cells were transfected with or without 100ng ARNT or ARNT2 expression vector with increasing 
amounts of Sim2 or Sim2s expression vector plus a CME-controlled luciferase reporter and ß-gal 
expression plasmids.  The amount of each plasmid per transfection (in ng) is indicated under the figure.  
Luciferase activity was increased in both Sim2 and Sim2s-transfected cells, but only when ARNT was 
present.  The degree of induction was Sim2-dependent as higher amounts of expression vector increased 
luciferase activity.  Again, Sim2s was better than Sim2 at inducing CME-controlled gene expression.  
*Luciferase expression is higher in the presence of SIM and Sim2s in comparison to no ARNT controls 
(p<0.005).  **Luciferase expression is higher in Sim2s cells in comparison to Sim2 cells (p<0.01). 
 
 
3.1.5. SIM-mediated regulation of a CME-controlled gene requires the 
transcriptional activation domain of ARNT 
     Confirmation of ARNT-dependent Sim2s transcriptional activation from a CME-
controlled gene is presented in Figure 28.  In these experiments, contransfection of a 
mutant ARNT (Arnt∆TAD), which is missing the transactivation domain, abolished the 
ability of Sim1, Sim2 and Sim2s to increase expression from a CME.  Expression of 
Arnt∆TAD repressed basal CME-mediated gene expression in the absence of external 
SIM proteins (Fig. 28).  Co-expression of Sim1 and ARNT resulted in significant 
reporter gene expression that was abolished when ARNT was replaced with the 
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Arnt∆TAD expression vector.  A similar effect was seen with Sim2, but the degree of 
gene activation was significantly lower than was seen with Sim1.  Surprisingly, Sim2s 
was almost as potent as Sim1 in activating CME-controlled gene expression (Fig. 28).  
As observed in Sim1, this effect was completely abolished when ARNT∆TAD was 
substituted for ARNT, implying that this effect is entirely mediated by the activation 
domain of ARNT. 
 
 
Figure 28. Sim-mediated regulation of a CME-controlled gene requires the transcriptional 
activation domain of ARNT.  Control (pcDNA), Sim1, Sim2 or Sim2s expression plasmids were co-
transfected with pCME-luc and a ß-gal expression vector along with full length Arnt (white bars) or a 
mutant Arnt (black bars) expression plasmid.  In the presence of full length ARNT, robust luciferase 
expression was detected in Sim1 and Sim2s-transfected cells and to a lesser extent, in Sim2 cells.  This 
effect was abolished when ARNT was replaced with the transactivation mutant ARNT (ARNTΔTAD).  
*Luciferase expression is repressed in the presence of ARNTΔTAD (p<0.03).  **Luciferase expression is 
induced in the presence of Sim1 (p<0.02).  ***Luciferase expression is increased in the presence of Sim2 
in comparison to pcDNA control cells (p<0.01).  §Luciferase expression is higher in the presence of Sim2s 
in comparison to pcDNA-transfected cells (p<0.0003).  †Luciferase expression is inhibited in the presence 
of ARNTΔTAD (p<0.001). 
 
 
     To confirm the interactions between Sim2 and Sim2s on a CME, ChIPs were 
performed on CME-luc transfected control- and Sim2/ARNT or Sim2s/ARNT cells.  
Chromatin was immunoprecipitated with an anti-SIM2 antibody that recognizes both 
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SIM2 and SIM2s, and was analyzed for CME binding using a set of PCR primers 
specific for the CME reporter plasmid.  The presence of Sim2 on the CME was 
detectable in control cells, most likely due to endogenous Sim2 (data not shown).  More 
importantly, the presence of both Sim2 and Sim2s on the CME was elevated in Sim2-
transfected cells (Fig. 29).  These data suggest that the differential outcomes of Sim2 
isoform binding to a CME are not due to changes in DNA binding. 
 
 
Figure 29. Sim2 and Sim2s bind directly to a CME.  HEK-293T cells were co-transfected with CME-
luc and either a control (pcDNA), Sim2 or Sim2s expression vector.  Following formalin cross-linking, 
chromatin was sonicated and immunoprecipitated with an anti-Sim2 antibody and analyzed by PCR using 
primers that recognize the CME binding site in the reporter vector.  Background was determined using 
IgG instead of anti-SIM2.  The relatively small amount of product obtained in control cells is comparable 
to the IgG control, and may reflect binding of endogenous Sim2 to the CME.  In contrast, both Sim2 and 
Sim2s binding to the CME was readily apparent in Sim2-transfected cells.  Neg; PCR negative control 
containing no template. 
 
 
3.2. Sim2s is an important regulator of mammary gland development 
3.2.1. Sim2s is the predominant Sim2 isoform expressed in many mouse tissues 
     Sim expression was analyzed in mouse tissues by RT-PCR and real time RT-PCR 
(Fig. 30).  Sim1 was expressed at high levels in kidney, brain, lung and skeletal muscle 
(Fig. 30A).  In contrast, Sim2 and Sim2s were expressed at high levels in kidney and 
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skeletal muscle.  The ratio of Sim2s and Sim2 mRNA expressed in kidney and skeletal 
muscle appeared to differ, suggesting that their expression is controlled in a tissue-
specific manner.  Therefore, expression of both isoforms of Sim2 were determined in 
kidney, liver and skeletal muscle by RT-PCR using a common forward primer located in 
exon 9, and both Sim2- and Sim2s-specific reverse primers located in exons 11 and "s", 
respectively.  As expected, neither Sim2 isoform was detected in liver, but kidney and 
skeletal muscle expressed both Sim2 and Sim2s in different relative amounts (Fig. 30B).  
In agreement with our initial analyses (Fig. 30A), kidney expressed slightly more Sim2s 
than Sim2 while skeletal muscle expressed significantly more Sim2 than Sim2s.  
Quantitative real time RT-PCR analyses of kidney, liver and skeletal muscle RNA for 
total Sim2 (Fig. 30C), Sim2s (Fig. 30D) and full length Sim2 (Fig. 30E) corroborated 
our PCR analyses and found that, overall, skeletal muscle contains significantly higher 
levels of full length Sim2 mRNA than kidney. 
3.2.2. Expression patterns of mSim2 in HC11 cells 
     Sim2s was also the predominant form of Sim2 in HC11 mouse mammary epithelial 
cell line without any Sim2L expression.  Interestingly, we found there was more protein 
expression in differentiated than undifferentiated HC11 cells (Fig. 31B), while there was 
no difference in the mRNA expression level (Fig. 31A).   
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Figure 30. Tissue-specific expression of mouse Sim genes.  A. RT-PCR analysis of Sim1, Sim2 and 
Sim2s expression in various mouse tissues.  Total RNA from the indicated tissues (BRN; brain, HRT; 
heart, KID; kidney, LVR; liver, LNG; lung, SKM; skeletal muscle, SPL; spleen, UTR; uterus) was 
subjected to RT-PCR as described under Materials and Methods.  Sim1 was expressed at relatively high 
levels in mouse kidney>brain>lung>skeletal muscle. Sim2s was expressed at high levels in kidney and 
was detectable in skeletal muscle. Full-length Sim2 was detected in skeletal muscle>kidney.  B. Co-
amplification of Sim2 and Sim2s by RTPCR in mouse kidney, liver and skeletal muscle.  RT-PCR 
reactions were performed on total RNA from mouse tissues using a single forward primer and both Sim2s-, 
and Sim2 long form-specific reverse primers.  Sizes of DNA ladder are indicated to the left.  Neither 
isoform of Sim2 was detectable in liver, but both Sim2 and Sim2s were detected in kidney and skeletal 
muscle.  The relative amounts of Sim2 and Sim2s expressed in these tissues differed with kidney 
expressing more Sim2s than Sim2 and vice versa in skeletal muscle.  C-E.  Real time PCR analyses of 
mouse kidney, liver and skeletal muscle mRNA for total Sim2 (C), Sim2s (D) and full-length Sim2 (E). 
 
 
Figure 31. Expression pattern of mSim2 in HC11 cells.  A. Expression of mSim2 mRNA in 
undifferentiated (UND) and differentiated (DIF) HC11 cells detectecd by RT-PCR.  B. Expression of 
mSim2s protein in undifferentiated and differentiated HC11 cells detected by Western blot.  mSim2-
pcDNA (pmSim2) was used as positive control and GAPDH was used as internal control. 
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3.2.3. Sim2s is the predominant Sim2 isoform in the mouse mammary glands 
 
 
 
Figure 32. Expression of Sim genes in the mouse mammary gland.   A. Expression of Sim genes in the 
developing mouse mammary gland.  RT-PCR was performed on mammary gland RNA isolated from 4- 
and 10-week old virgin mice (V4 and V10), mice at days 6 and 16 of pregnancy (P6 and P16), mice at 
days 1 and 7 of lactation (L1 and L7) and mice at day 3 of involution (I3).  Kidney RNA (Kid) was 
included as a positive control.  B. Quantification of Sim2 gene expression in the developing mouse 
mammary gland.   Real-time RT-PCR was used to quantify Sim2 mRNA levels in the developing 
mammary gland. 
 
 
     In the mammary gland, neither Sim1 nor the long form of Sim2 was detectable at any 
developmental time point (Fig. 32A).   However, a form of Sim2 was expressed and 
developmentally regulated throughout pregnancy, lactation and involution (panSim2, Fig. 
32A).   Sim2s expression was similar to total Sim2 suggesting that Sim2s is the 
predominant Sim2 isoform expressed in the mammary gland.   Quantitative real time 
PCR supported this observation and indicated that Sim2s expression is high in young 
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virgin mice and decreases in early adulthood (Fig. 32B).   During pregnancy, Sim2s 
expression remains low, but begins increasing near parturition and through lactation.   
By involution day 3, Sim2s levels decrease back to adult nulliparous baseline levels (Fig. 
32B).    
3.2.4. Mammary gland Sim2s expression is developmentally regulated 
     Mammary gland development is a complicated process involving positive and 
negative interactions within and between the epithelial and stromal compartments.   
Since our data showed that Sim2 message levels are developmentally regulated in the 
mouse mammary gland, we performed experiments to better characterize the spatial and 
temporal expression patterns of mammary Sim2s.   To do this, sections of mouse 
mammary glands from different stages of development were analyzed by 
immunostaining using a human SIM2s-specific antibody.   Our results indicate that 
Sim2s is present in the condensed stroma surrounding the terminal end buds in the 
actively developing 4-week old mammary gland (Fig. 33A-B).   Sim2s remains stromal 
through late virgin development, but is detectable in both the epithelial and stromal 
compartments by 10-weeks of age (Fig. 33C).   Interestingly, Sim2s is only present in 
luminal epithelial cells during pregnancy and lactation (Fig. 33D) and is significantly 
decreased throughout involution (data not shown).   Co-immunostaining of 4-week old 
virgin mammary glands for Sim2s and Keratin 14, a myoepithelial cell marker, indicated 
that Sim2s is entirely stromal at this stage, and is not expressed in myoepithelial cells 
(Fig. 33E-F).  Negative controls for immunostain secondary antibody and 
immunofluoresence secondary antibodies are also presented in Figure 33G and 33H, 
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respectively. 
 
 
 
Figure 33. Immunolocalization of Sim2 expression in mouse mammary gland.  A-B.  
Immunolocalization of mSim2s protein in a  4-week old virgin mouse mammary gland.  Lateral (A) and 
cross-sectional (B)  view of a 4 week-old mouse mammary duct.   C. Immunolocalization of Sim2s protein 
in a  10-week old virgin mouse mammary gland.  D. Immunolocalization of Sim2s protein in a day 7 
lactating mouse mammary gland.   E-F. Co-localization of Sim2s (red) and Keratin-14 (green) in 4 week-
old mouse mammary gland.  G. Negative control for immunostain secondary antibody.   Donkey anti-goat.   
H. Negative control for immunofluoresence secondary antibodies.  Co-stain with goat anti-rabbit and 
donkey anti-goat. 
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3.3. Sim2s is mammary tumor suppressor gene 
3.3.1. SIM2s is down-regulated in breast cancer cells and primary breast cancer 
samples 
 
 
Figure 34. Single minded mRNA expression in breast epithelial- and cancer-derived cell lines.  A. 
Schematic representation of SIM2 and SIM2s mRNAs with relative positions of PCR primers used in 
these studies indicated.   Exons are indicated by numbered boxes.   Structural motifs are represented by 
bars:  bHLH (basic helix-loop-helix domain, black bar), PAS (Per-Arnt-Sim domains, stripped bars), 
Pro/Ser (proline/serine-rich, white bar) and Pro/Ala (proline/alanine-rich, grey bar) regions implicated in 
harboring SIM2 repression domains.   PCR primer locations are indicated by name and arrows.   B. 
Analyses of total SIM2 (pan SIM2), SIM2s, SIM2 long form (SIM2L) and SIM1 message levels in normal 
human breast and breast cancer-derived cell lines by RT-PCR.   Cell lines are indicated at the top of the 
figure.   C. Quantification of total SIM2 expression in human breast and breast cancer cells by real time 
RT-PCR.   Data was quantified by the ∆∆CT method using TATA binding protein mRNA as the 
normalizer.   
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     To determine if SIM2 plays a role in breast cancer, we examined a panel of human 
breast- and breast cancer-derived cell lines for SIM gene expression by standard and real 
time RT-PCR.   The relative positions of the SIM2-specific primers used in these 
analyses are indicated in Figure 34A.   The 21T cell line series was established from 
normal breast (16N) and primary (21NT and 21PT) and metastatic (21MT1 and 21MT2) 
breast tumor specimens from a single patient with infiltrating ductal and intraductal 
carcinoma (Band et al., 1990 & 1991; Coletta et al., 2004).   Together with other human 
breast- and breast cancer-derived cell lines (i.e.  MCF10A, MCF7, ZR75, T47D, MDA-
MB-231, MDA-MB-453 and MDA-MB-435 cells), these cells provide a useful model to 
evaluate gene expression in a simulated tumor progression series.   Total SIM2 mRNA 
was detectable at the highest levels in MCF10A and 16N normal breast epithelial cells 
(Fig. 34B).   SIM2 expression was markedly decreased in the 21T breast cancer 
progression series and in the other breast cancer cell lines examined.    
     RT-PCR analyses using primers to discern between the short and long forms of SIM2 
indicated that SIM2-positive cell lines expressed the SIM2s isoform, with the exception 
of MCF10A cells, which expressed only the long form of SIM2 (Fig. 34B).   In contrast, 
SIM1 mRNA was not detected in any of the breast cells, but was abundant in kidney-
derived HEK 293 cells.    
     Quantification of relative SIM2 expression in these cells by real time RT-PCR 
corroborated the RT-PCR results and confirmed that SIM2 expression is highest in non-
transformed MCF10A and 16N cells, is much lower in the non-invasive, estrogen 
receptor positive MCF-7, T47D and ZR75 breast cancer cells and is dramatically 
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decreased in the highly invasive estrogen receptor negative MDA-MB-453 and MDA-
MB-435 cell lines (Fig. 34C).    
     A subset of these cell lines was analyzed for SIM2s protein levels by Western blot 
(Fig. 35).   In agreement with the PCR data, SIM2s protein was only detectable in MCF-
7 and T47D cells.   Interestingly, SIM2s protein was not detected in MDA-MB-231 cells 
despite having observable levels of SIM2s message.   These results suggest that SIM2s is 
the most prevalent isoform of SIM2 expressed in human breast-derived cell lines. 
 
 
Figure 35. Western analysis of SIM2s expression in representative breast cancer cells using a SIM2s 
specific antibody. 
 
 
     This was confirmed by immunohistochemical staining of normal breast and primary 
breast tumor tissues using a SIM2s-specific antibody.   SIM2s protein was readily 
detectable in the ductal epithelium of normal breast tissue (Fig. 36A), whereas SIM2s 
was not present in 18 out of 25 (72%) breast tumor samples (Fig. 36B-D).    
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Figure 36. Immunohistochemical analysis of SIM2s protein levels in normal human breast and 
breast tumor tissues.   A human breast cancer tissue array (Chemicon) containing 5 normal and 25 breast 
tumor tissue sections (in duplicate) was analyzed for SIM2s protein levels by immunohistochemistry as 
described in Materials and Methods.  A. Representative image of a normal human breast tissue sample 
showing ductal epithelial cells with high levels of SIM2s staining.   B. Representative image of a SIM2s-
positive breast tumor sample.   Note that the majority of breast tumor samples (18 out of 25, or 72%) were 
SIM2s negative.   When present in tumor samples, SIM2s staining was considerably less intense than that 
observed in the normal breast tissues.   C-D. Representative images of SIM2s-negative human breast 
tumor sections. 
 
 
3.3.2. Inhibition of breast cancer growth by SIM2s 
     Our data indicates that SIM2s expression is lost during breast cancer progression.   
To determine if SIM2s has tumor suppressor activity, MDA-MB-435 breast cancer cells 
were transduced with a recombinant retrovirus expressing SIM2s.   Re-establishment of 
SIM2s expression was confirmed by RT-PCR (Fig. 37A) and immunofluorescence (Fig. 
37B).   
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Figure 37. Reintroduction of SIM2s into MDA-MB-435 cells.  MDA-MB-435 cells were infected with 
recombinant retroviruses expressing SIM2s or Puro only (Control vector).   Two days after infection, 
puromycin was added to the cell medium and selection continued for 5 days.  A. Confirmation of SIM2s 
expression in SIM2s-infected MDA-MB-435 cells by RT-PCR.  B. Confirmation of SIM2s protein 
expression by immunofluorescence using a SIM2s polyclonal antibody. 
 
      Quantification of colonies after two weeks of selection showed that SIM2s 
significantly inhibited colony growth in MDA-MB-435 cells (Fig. 38A).   Subsequently, 
a 7-day proliferation assay confirmed that stable expression of SIM2s blocked MDA-
MB-435 cell growth (Fig. 38B).   In addition to pooled samples, individual colonies of 
control- and SIM2s-transduced cells were isolated by serial dilution; however, these 
clones lost SIM2s expression after a few weeks of selection (data not shown), further 
supporting a role for SIM2s in inhibiting tumor cell growth.   
     The ability to grow in soft agar is a hallmark of the transformed phenotype.   To 
assess if re-introduction of SIM2s reduces anchorage-independent growth of breast 
cancer cells, vector control- and SIM2s-infected MDA-MB-435 cells were plated in soft 
agar and assayed for colony formation over two weeks.   Gross observation revealed that 
SIM2s-infected cells do not grow as well in soft agar as the control cells (Fig. 39).   
After 14 days, the number of colonies greater than 200µm was significantly lower in the 
SIM2s-infected cells (Fig. 39). 
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Figure 38. SIM2s suppresses growth of MDA-MB-435 breast cancer cells.   A. Re-introduction of 
SIM2s inhibits expansion of MDA-MB-435 colonies under puromycin selection in comparison to vector-
only cells.   The number of colonies formed after two weeks of puromycin selection was lower 
(*P<0.0001) in SIM2s-transduced cells than in control cells as determined by Gimsa staining.  The values 
shown are the mean ± SE of three separate samples.  B. SIM2s inhibits breast cancer cell proliferation.   
Equal numbers of control and SIM2s-expressing cells were plated in six-well plates and counted daily 
over a 7-day period.   Significant differences in cell proliferation due to reintroduction of SIM2s were 
apparent by day 5 (*P<0.001) and continued through day 7 (**P<0.0001).   Data represent results from at 
least two independent experiments.   The values shown are the mean ± SE of triplicates. 
 
 
 
Figure 39. Reintroduction of SIM2s reduces anchorage-independent growth of breast cancer cells.  
SIM2s inhibits MDA-MB-435 cell growth on soft agar.   The left portion of the figures shows 
representative images of colonies that grew on soft agar in control (top) and SIM2s (bottom) MDA-MB-
435 cells.   Following 14 days of growth, the number of colonies greater than 200 µm in size were counted 
(right portion of figure).   Re-introduction of SIM2s into MDA-MB-435 cells reduced colony formation on 
soft agar (* P<0.005).  Values are the mean number of colonies ± SE of three plates/group. 
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3.3.3. SIM2s induces G0/G1 cell cycle arrest 
     Reintroduction of SIM2s led to G0/G1 cell cycle arrest in MDA-MB-435 breast 
cancer cells. Compared with Control, SIM2-transduced MDA-MB-435 cells showed 
over 10% increase in G0/G1 phase and about 7% decrease in G2/M phase (Fig. 40). 
 
 
Figure 40. Reintroduction of SIM2s induced G0/G1 cell cycle arrest in MDA-MB-435 cells.   
 
 
3.3.4. SIM2s regulates genes involved in cancer initiation and progression 
     Identification of SIM2s target genes by microarray analysis.  We found that SIM2s 
regulates many genes involved in cancer initiation and progression including Wnt5b, 
Interleukin 21, Melanin A and MMP3 (Fig. 41A).  This result was confirmed by Real 
Time PCR for Interleukin 21 and WNT5B (41B). 
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Figure 41. Identification and confirmation of SIM2s target genes by microarray analysis.  A.  
Microarray analysis of MDA435 and MDA435-SIM2s cells (Codelink Bioarrays).   Genes shown were 
regulated by at least 4-fold and p<0.001.   B.  Confirmation of SIM2s-dependentt regulation of Wnt5b and 
Interleukin-21 by real time RT-PCR. 
 
 
3.3.5. Loss of mammary Sim2 expression results in loss of epithelial characteristics 
and hyperplasia 
Since Sim2-/- mice die shortly after birth, we dissected mammary glands from newborn 
Sim2-/- pups and placed them into the cleared fat pads of nude mice.   After 8 weeks of 
outgrowth, the transplanted glands were removed for histological analyses.   Whole 
mounts of Sim2-/- mammary glands initially suggested that loss of Sim2 stimulates 
alveolar development since Sim2-/- glands appear to have a significant increase in the 
number of alveolar buds on the ductal tree (compare Figures 42A and 42B).   However, 
H&E staining of sections through these glands indicate that the ducts of Sim2-/- 
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mammary glands failed to hollow (compare Figures 42C and 42D) and that the alveolar-
like structures are actually solid masses of cells that appear to be spreading into the 
surrounding stroma (compare Figures 42E and 42F).   
 
 
 
Figure 42. Mammary gland morphology in Sim2-/- mice.  A & B.  Whole mount analyses of wild type 
and Sim2s-/- mammary gland outgrowths 8 weeks post-transplantation.  C-F. H&E staining of wild type 
and Sim2-/- mammary gland outgrowths.    
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Figure 43. Trichrome staining of mouse mammary gland sections.   Asterisk indicates hollow duct 
found in normal, but not Sim2-/- mammary glands.   Arrow indicates ruffling edge of epithelial cells and 
thinning basement membrane. 
 
     Masson’s trichrome staining of sections showed that the cells present in these masses 
are non-polarized and the collagen-rich basement membrane surrounding them is 
disorganized and reduced in thickness (compare Figure 43A to 43B and Figures 43C to 
43D).  In addition, the cells adjacent to the basement membrane in Sim2-/- mammary 
glands have ruffled edges suggesting that they are actively degrading the basement 
membrane and migrating into the surrounding stroma (arrow in Figure 43D).   
Furthermore, Sim2s heterozygote mice have an elevated frequency and severity of focal 
ductal dysplasia, demonstrating that loss of one copy of Sim2s also affects mammary 
gland development (data not shown).   These results suggest that the cells in Sim2-/- 
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mammary glands are undergoing an epithelial to mesenchymal transition and provide 
strong support for our hypothesis that SIM2s is an important mammary tumor suppressor 
gene. 
 
3.4.  SIM2s is a metastasis inhibitor 
3.4.1. SIM2s inhibits metastasis and invasion 
     Since we found that SIM2s expression is inversely related to cellular invasiveness 
(Fig. 34), we next wanted to determine if SIM2s affected the invasive potential of MDA-
MB-435 cells.   Control- and SIM2s-transduced cells were grown in a Matrigel-coated 
modified Boyden chamber, which mimics the three-step process of invasion: adhesion, 
proteolytic dissolution of the extracellular matrix (ECM) and migration.   Before the 
invasion assay, we also tested the migration rate of Control- and SIM2s-transduced cells.  
Consistent with our hypothesis that SIM2s is a tumor suppressor, forced expression of 
SIM2s significantly blocked both migration (Fig 44A) and invasion (Fig 44B) over 80% 
in comparison to the control cell line.   
3.4.2. Loss of Sim2 leads to an epithelial to mesenchymal transition (EMT) in the 
mouse mammary gland 
     Since Sim2-/- mammary glands appear to be undergoing an EMT, we examined 
transplanted wild type and Sim2-/- mammary glands for E-cadherin levels by 
immunofluorescence.  E-cadherin expression was dramatically decreased in Sim2-/- 
glands (compare Figures 45A and 45B).   Confirmation of Sim2 expression in WT and 
Sim2-/- glands is shown in Figures 45E and 45F. 
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Figure 44. SIM2s inhibits both migration and invasion.  SIM2s-dependent inhibition of migration and 
invasion potential in MDA-MB-435 cells.   A. Migration assay.  B. Invasion assay.   MDA-MB-435 cells 
(1 × 105 cells per sample) were plated in serum free media in the upper compartment of a modified 
Boyden chamber coated with Matrigel.   The lower compartment contained 10% FBS to serve as the 
chemo-attractant.   After 24 hr, the number of cells that had migrated to the bottom surface of the 
membrane were stained with Diff-Quick and counted.   Less SIM2s-expressing cells were able to invade 
and migrate to the lower chamber (P<0.005).   Values are the average number of cells per five fields per 
membrane of three separate plates, and are expressed as percent of control (mean ± SE). 
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Figure 45. E-Cadherin and Sim2s expression in wild type and Sim2-/- mouse mammary glands.  A-D. 
Loss of E-cadherin expression in Sim2-/- mammary glands.   Indirect immunofluorescent staining for E-
cadherin (A and B) and DAPI (C and D) in WT (A and C) and Sim2-/- (B and D) mammary glands.  E-F 
Confirmation of Sim2 loss in Sim2-/- mammary glands Immunolocalization of Sim2s expression in wild 
type (E) and Sim2-/- (F) mammary glands by immunostaining. 
 
 
3.4.3. SIM2s inhibits MMP gene expression and activity   
     The ability of SIM2s to decrease invasiveness of MDA-MB-435 cells suggested that 
SIM2s affects one or more genes responsible for ECM remodeling.  Tissue remodeling 
requires degradation of the basement membrane and surrounding extracellular matrix.   
This occurs during normal mammary gland development, and under pathological 
conditions such as tumor progression and metastasis.   Because MMPs are involved in 
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breast cancer initiation, proliferation and invasion, RT-PCR analyses of control- and 
SIM2s-transduced cells for expression of several MMP genes was performed.  MMP 2, 3, 
9, and 10 was decreased by SIM2s (Fig 46A).  The effects of SIM2s on MMP2 
expression correlated with MMP2 enzymatic activity as determined by gelatin gel 
zymography (Fig. 46B).  Real time analysis for the MMP2 again confirmed that SIM2s 
decreases MMP2 mRNA expression level (Fig. 46C). 
 
 
Figure 46. Down regulation of MMP expression and activity by SIM2s.   A.  Analysis of MMP gene 
expression  in MDA-MB-435 and MDA-MB-435-SIM2s cells by RT-PCR.  B. Analysis of MMP2 activity 
in MDA-MB-435 and MDA-MB-435-SIM2s cells using gelatin gel zymography.  C. Quantification of 
MMP2 and MMP3 expression in MDA-MB-435 and MDA-MB-435-SIM2s cells by real time RT-PCR. 
 
 
     Of the MMP genes analyzed in these experiments, MMP3 was most significantly 
repressed by SIM2s.   This finding was noteworthy as MMP3 is known to play important 
roles in cell migration, breast cancer progression and EMT (Ioachim et al., 1998; La 
Rocca et al., 2004).   To better characterize the effects of SIM2s on MMP3 expression, 
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control- and SIM2s-transduced MDA-MB-435 cells were analyzed for MMP3 mRNA 
by real time RT-PCR.   SIM2s significantly repressed both basal and PMA-induced 
MMP3 expression (Fig. 47A).   The effects of SIM2s on MMP3 expression correlated 
with MMP3 protein and enzymatic activity as determined by Western blot and casein gel 
zymography (Fig. 47B).   
 
 
Figure 47. SIM2s-dependent inhibition of MMP3 expression and enzymatic activity in MDA-MB-
435 cells.  A.  SIM2s inhibits basal and PMA-induced MMP3 expression in MDA-MB-435 cells.   
Quantification of MMP3 mRNA levels in control and SIM2s- transfected MDA-MB-435 cells by real time 
RT-PCR.  The values shown are the mean ± SE of three separate samples, *P<0.005.  B. Casein 
zymography and Western Blot analysis of MMP3 activity and protein, respectively, in control and SIM2s-
infected cells. 
 
 
3.4.4. Loss of Sim2 leads to results in increase in MMP3 
     The effect of SIM2s on MMP3 expression was also confirmed in the mouse 
mammary glands.  We examined transplanted wild type and Sim2-/- mouse mammary 
glands for MMP3 levels using immunohistochemistry.  MMP3 expression was 
dramatically increased in Sim2-/- glands (Fig. 48A & B).   Confirmation of Sim2 
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expression in WT and Sim2-/- glands is shown in Figures 45E and 45F.  
 
 
Figure 48. MMP3 expression in wild type and Sim2-/- mouse mammary glands.  Loss of Sim2 results 
in increase in MMP3. 
 
     We also found that Sim2 -/- mammary gland is highly proliferating by 
immunohistochemistry for a proliferation marker, Ki-67.  The expression level of Ki-67 
was 4 times higher in the Sim2-/- mice, comparing with wild type mice (Fig. 49).   
 
 
Figure 49. Proliferation in wild type and Sim2-/- mice. 
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3.4.5. SIM2s directly binds the MMP3 promoter to repress MMP3 expression 
 
 
Figure 50. SIM2s represses MMP3 transcription by binding the MMP3 promoter.  A. Effects of 
SIM2s on basal and PMA-induced expression from human MMP3 reporter constructs.  MDAMB-435 
cells containing -2264 to +37 of the human MMP3 promoter were tested for basal (open bars) and PMA-
induced (black bars) luciferase expression in the presence of increasing amounts of SIM2s expression 
construct.  Plasmids (0.45 µg MMP3-luc construct, various amounts of pcDNA3-SIM2sHA [0.0, 0.4, 1.0 
or 2.0 µg] plus pcDNA3 [to equal 2.0 µg total expression construct] and 0.2µg ß-Gal expression vector) 
were introduced into MDA-MB-435 cells by transfection.  Following a 24 hr recovery period, fresh 
medium containing DMSO or PMA (50 ng/ml) was added and luciferase and ß-galactosidase activities 
were measured 24 hr later.  The values shown are the means ± SE for three separate plates.  (B) 
Transfected SIM2s binds the MMP3-Luc reporter plasmid.  293t cells were co-transfected with the -2264 
to +37 MMP3-Luc reporter and either a control (pcDNA3) or SIM2s expression vector.  Following 
formalin crosslinking, chromatin was sonicated and immunoprecipitated with anti-SIM2 (Chemicon) or 
IgG (negative control) antibodies and analyzed by PCR using primers that target the reporter vector.  (C) 
SIM2s binds the endogenous MMP3 promoter in SIM2s-transduced MDA-MB-435 cells.  Chromatin 
immunoprecipitation analysis of the MMP3 and E-Cadherin (negative control) promoters in control and 
MDA-MB-435-SIM2s cells. 
 
 
     To determine if the effects of SIM2s on MMP3 expression are mediated at the 
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transcriptional level, a human MMP3 promoter-controlled luciferase reporter gene was 
analyzed for SIM2s responsiveness.  MDA-MB-435 cells were transfected with a 
luciferase reporter gene under the control of the human MMP3 promoter in the presence 
or absence of SIM2s.  SIM2s significantly decreased basal and PMA-induced luciferase 
activity in a dose-dependent manner (Fig. 50A).  Consistent with SIM2s functioning as a 
transcriptional repressor, we determined by ChIP analyses that SIM2s bound the MMP3-
Luc reporter in the presence of transfected SIM2s (Fig. 50B) and also interacted with the 
endogenous MMP3 promoter in SIM2s-transduced MDA-MB-435 cells (Fig. 50C).  No 
SIM2s binding was observed on the E-Cadherin promoter, which was used as a negative 
control (Fig. 50C). 
3.4.6. SIM2s inhibits MMP3 expression by inhibiting AP-1 binding to the MMP3 
promoter  
     To determine if the effects of SIM2s on MMP3 expression are mediated at the 
transcriptional level, a human MMP3 promoter-controlled luciferase reporter gene was 
analyzed for SIM2s responsiveness.   Introduction of a SIM2s expression construct 
significantly decreased basal, as well as PMA-induced, luciferase expression from an 
MMP3-luc reporter (Fig. 51A).   Various 5' deletions of the MMP3 regulatory region (up 
to -288) were also significantly inhibited by SIM2s, implying that a sequence, or 
sequences, between -288 and +20 of the human MMP3 promoter are responsible for 
mediating the repressive effects of SIM2s on MMP3 expression (Fig. 51A).   
MMP3 expression is low in normal tissues but can be up regulated following growth 
factor and/or cytokine stimulation.   Many of the pathways regulating MMP3 expression 
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converge at an AP-1 site located between -75 and -65 of the MMP3 promoter, which 
binds JUN and FOS heterodimers.   Increased AP-1 activation has been shown to play a 
role in transformation and invasion, most notably through up-regulation of MMPs.  
 
 
 
Figure 51. SIM2s represses the human MMP3 promoter by inhibiting AP-1 binding.  A.  Effects of 
SIM2s on basal and PMA-induced expression from human MMP3 reporter constructs.   MDA-MB-435 
cells containing various 5' deletions of the human MMP3 promoter, or a consensus AP-1 element, were 
tested for basal (open bars) and PMA-induced (black bars) luciferase expression in the presence of 
increasing amounts of SIM2s expression construct.   Plasmids (0.45 µg MMP3-luc construct, various 
amounts of pcDNA3-SIM2sHA [0.0, 0.4, 1.0 or 2.0 µg] plus pcDNA3 [to equal 2.0 µg total expression 
construct] and 0.2µg ß-Gal expression vector) were introduced into MDA-MB-435 cells by transfection.   
Following a 24 hr recovery period, fresh medium containing DMSO or PMA (50 ng/ml) was added and 
luciferase and ß-galactosidase activities were measured 24 hr later.   The values shown are the means ± SE 
for three separate plates.   B. SIM2s blocks AP-1 binding to the MMP3 promoter.   MDA-MB-435 cells 
were co-transfected with the -288 to +20 MMP3-Luc reporter and either a control (pcDNA3) or SIM2s 
expression vector.   Following formalin cross-linking, chromatin was sonicated and immunoprecipitated 
with anti-JUN, anti-SIM2 or IgG (negative control) antibodies and analyzed by PCR using primers that 
target the reporter vector. 
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     To determine if SIM2s mediates repression of MMP3 through this AP-1 site, MDA-
MB-435 cells were co-transfected with a SIM2s expression construct and a consensus 
AP-1 luciferase reporter.   Significant repression of basal and PMA-induced luciferase 
expression from the AP-1 reporter was observed in the presence of SIM2s (Fig. 51A).    
This response correlated with a decrease in JUN binding to the MMP3 AP-1 element as 
determined by ChIP analysis (Fig. 51B).   These findings are similar to previous studies 
demonstrating that the Retinoic Acid and Glucocorticoid Receptors can repress MMP3 
expression by inhibiting AP-1 binding (Dedieu & Lefebvre, 2006; Nicholson et al., 
1990). 
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IV. DISCUSSION* 
 
4.1. Differential transcriptional regulation by mSim2s 
 
     Transcriptional regulation occurs through multiple distinct mechanisms involving 
negative and positive interactions between regulatory factors.  The mammalian SIM 
proteins are unique members of the bHLH-PAS family since they can exert negative 
effects on transcription.  It has been determined that the repressive effects of SIM2 are 
mediated by two domains in its carboxyl terminus.  One of these domains is rich in Pro 
and Ser residues while the other is Pro and Ala rich.  These repressive domains appear to 
be non-specific as SIM2 can suppress activation of a Gal4 activation domain on a 
thymidine kinase promoter (Moffett & Pelletier, 2000; Probst et al., 1997) as well as 
ARNT-mediated transactivation.  Similar hydrophobic domains are present in other 
transcriptional repressors including the Drosophila Kruppel transcription factors and 
Even-skipped, which inhibit transactivation by competing with TBP for TATA box 
binding thus preventing assembly of the preinitiation complex (McKay et al., 1999).        
     In this study, we have shown that mouse Sim2s, a splice variant of Sim2, has 
differential effects on CME- and HRE-mediated gene expression.  Sim2s is less potent 
than full length Sim2 at repressing HIF1-α (Fig. 24), and can activate expression of a 
gene controlled by the Drosophila toll gene CME via ARNT's transactivation domain 
                                                 
* Parts of this section are reprinted from Metz et al., 2006, J Biol Chem, 281(16), 10839-10848, Copyright 
© 2006 by the American Society for Biochemistry and Molecular Biology and Kwak et al., 2006, 
Carcinogenesis, in progress, Copyright © 2006 by Oxford University Press. 
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(Fig. 26).  The hypo-suppressive effects of Sim2s are not surprising given that Sim2s is 
missing the Pro/Ala-rich repression domain.  What is surprising is that Sim2s is just as 
repressive as Sim2 on TCDD-mediated gene expression through a DRE (Fig. 25) and is 
able to increase expression of a CME-controlled gene (Fig. 26).  These data suggest a 
model in which the response element dictates transcription factor domain-dependent 
suppression or activation. 
     On an HRE, both the Pro/Ser-rich and Pro/Ala-rich domains of Sim2 appear to exert 
repressive effects.  This is based on the observation that Sim2s, which is missing the 
Pro/Ala-rich region, still exerts a repressive effect although it is not as strong as that 
observed with Sim2 (Fig. 24).  In the case of the DRE, both Sim2 and Sim2s can repress 
gene expression to an equal extent suggesting that only the Pro/Ser-rich domain 
mediates Sim2-mediated repression from a DRE.  In contrast, Sim2s can activate 
expression from a CME apparently by acting as a docking protein for ARNT (Figs.  28 
and 29).  This implies that the Pro/Ala-rich sequence present in Sim2, but not Sim2s, 
exerts a negative effect on CME-mediated gene expression.  As Sim2s lacks this domain, 
interactions between Sim2s and ARNT on a CME result in ARNT-mediated activation 
of Sim2s targets. 
     Interactions between transcription factors and their cognate response elements are 
influenced by sequence flanking the core binding motif.  Whitelaw, et al.  (1994) 
reported that a region of the AHR ligand-binding domain exerted different degrees of 
repression on different DNA targets thus, providing an example of such promoter-
specific influence on transcription factor function in the bHLH-PAS family (Whitelaw et 
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al., 1994).  These response element-specific effects are most likely due to DNA-
dependent conformational changes in the interacting factor, which may influence the 
ability of the transcription factor to recruit co-regulatory proteins to the promoter.  For 
example, the POU domain-containing transcription factor POU1F1 (a.k.a. PIT1) 
represses transcription when bound to its response element in the growth hormone gene, 
but induces expression through a similar element in the prolactin promoter.  This was 
shown by crystallography to be due to DNA-induced allosteric changes in PIT1 
confirmation resulting in differential coregulator recruitment (Scully et al., 2000).  In the 
case of SIM2s, such dynamic, DNA-mediated changes in transcriptional outcome may 
reflect the ability of SIM2s to exert differential effects on similar response elements.  
Further studies are necessary to elucidate the mechanisms governing SIM2s-mediated 
gene repression and activation. 
     In Drosophila, several SIM targets have been identified including slit, engrailed, 
breathless and spitz (Crews et al., 1992; Crews & Fan, 1999).  No surprisingly, HIF1-α 
regulates many of the mammalian homologs of these genes since HIF1-α can bind the 
same core response element.  Although definitive targets of SIM2 have not been 
identified in mammals, this study and others have shown that SIM2 can affect the 
actions of other bHLH-PAS proteins by active repression and interference (Moffett et al., 
1997; Woods & Whitelaw, 2002). 
 
4.2. Sim2s is an important regulator of normal mammary gland 
     Human SIM2s is expressed in normal kidney and tonsil as well as lung, and testes 
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(DeYoung et al., 2003a & b).  We have found that Sim2s expression in mice is 
comparable, with high levels of Sim2s mRNA detected in kidney and skeletal muscle 
(Fig. 30A).  Interestingly, the ratio of Sim2 to Sim2s differs between these tissues with 
Sim2s being expressed at higher levels than Sim2 in kidney and vice versa in skeletal 
muscle (Fig 30B).  The significance of Sim2 isoform predominance in these tissues is 
unknown, but presumably could have substantial effects as we have demonstrated 
differences between binding partner specificity (Fig. 22) and transcriptional activities 
between Sim2 and Sim2s.  Due to the complex interaction potential and overlapping 
expression patterns of Sim proteins and HIF1-α, a hypoxic switch has been proposed to 
operate in cells expressing both genes (Woods & Whitelaw, 2002).  Such a switch could 
have profound implications for environmental regulation of developmental signaling 
pathways as developmental stage and organ-specific differences in response to systemic 
hypoxia have been reported (Minchenko et al., 2003; Stroka et al., 2001).   
     We found that Sim2s is a predominant Sim2 isoform in mammary gland and 
developmentally regulated.   Sim2s expression is high in young virgin mice, decreases in 
early adulthood and remains low during pregnancy.  Sim2s expression begins increasing 
near parturition and through lactation, and then decreasing back to adult nulliparous 
baseline levels (Fig. 32).  As shown by immunostaining (Fig. 33), Sim2s was regulated 
not only temporally but also spatially in mouse mammary gland.  Sim2s is present in the 
condensed stroma surrounding the terminal end buds in 4-week and in both the epithelial 
and stromal compartments by 10-weeks of age.  Interestingly, Sim2s is only present in 
luminal epithelial cells during pregnancy and lactation, and then significantly decreased 
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throughout involution.  Similar to the role of dSim in regulating axon growth and 
development in the Drosophila CNS (Crews et al., 1992), these results support a role for 
Sim2s in modulating stromal-epithelial interactions during the early stages of mammary 
gland development.    Interestingly, expression of Sim2s was shown to be affected by 
cell differentiation as Sim2s expression levels increased upon differentiation of the 
HC11 cells (Fig. 31B).  This is in agreement with the result showing that Sim2s 
expression increases near parturition and through lactation, and confined only in the 
luminal epithelial cells during pregnancy and lactation (Fig. 33D).  This finding strongly 
implies that Sim2s plays a role at some stage of the differentiation program of mouse 
mammary epithelial cells.      
     Taken together, these results indicate that Sim2s is the predominant form of Sim 
expressed in the mouse mammary gland, and its expression is tightly regulated during 
adolescent development and throughout pregnancy.   These data support our hypothesis 
that Sim2s plays an important role during mammary gland development and 
differentiation. 
 
4.3. Sim2s is a mammary tumor suppressor gene 
     SIM2 was initially identified by positional cloning around the DS critical region of 
chromosome 21 and is believed to contribute to many of the physiological abnormalities 
associated with DS (Chrast et al., 2000; Ema et al., 1999).   In these studies, we present 
evidence that a splice variant of SIM2, SIM2s, has tumor suppressor activity when re-
expressed in invasive breast cancer cells.   We found that forced expression of SIM2s in 
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MDA-MB-435 cells significantly inhibited proliferation (Fig. 38), anchorage-
independent growth (Fig 39.) and invasion potential (Fig 44).  Expression of SIM2s in 
MDA-MB-435 cells also caused G1/S cell cycle arrest (Fig. 40).  Meng et al.  (2006) 
found G1/S cell cycle arrest in the SIM2-transfected PN12 cell line, derived from a rat 
adrenal medullary pheochromocytoma tumor.  The mRNA and protein expressions of 
cyclin E decreased in the SIM2-transfected cells, while p27 expression significantly 
increased. 
     The hypothesis that SIM2s has tumor suppressor activity is strongly supported by 
Sim2 knock out study.  In this study, we showed that loss of Sim2s in the mammary 
gland resulted in dramatically increased ductal branching, accelerated lobuloalveolar-
like precocious hyperplasia, and decreased cell apoptosis.  These results suggest that the 
cells in Sim2-/- mammary glands are undergoing an epithelial to mesenchymal transition 
and provide strong support for our hypothesis that SIM2s is an important mammary 
tumor suppressor gene. 
  
4.4. SIM2s is a metastasis inhibitor 
     E-cadherin is essential for the development and maintenance of mammary luminal 
epithelial cells (Boussadia et al., 2002).   E-cadherin mediated adhesion is regulated, in 
part, by β-catenin, which couples it to the actin cytoskeleton (Barth et al., 1997).   In 
addition to determining cell fate, cadherin-catenin complexes stabilize mammary gland 
architecture, dictate epithelial cell polarity, promote survival and inhibit motility.   
Inactivation of E-cadherin is associated with invasive breast cancer, premature apoptosis 
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and involution in mice.   Consequently, expression of a stabilized β-catenin in the mouse 
mammary gland causes precocious alveolar development, hyperplasia, delayed 
involution and mammary tumors (Imbert et al., 2001).   Sim2s-/- mammary glands lose 
E-cadherin expression and contain hyperplastic nodules (Figure 45), suggesting that 
Sim2s plays a role in regulating E-cadherin/ß-catenin signaling. 
     In this study, overexpression of SIM2s in MDA-MB-435 cells significantly inhibited 
invasion potential (Fig. 44).  The decrease in invasion appears to be due, in part, to 
SIM2s' ability to repress MMP3 expression through direct inhibition of AP-1 binding to 
the MMP3 promoter (Fig 50).   These results are consistent with the observation that 
SIM2 is a transcriptional repressor and imply that SIM2s is a mammary-specific tumor 
suppressor. 
     Matrix metalloproteases play a major role in a number of biological processes, 
including morphogenesis, polarity determination, apoptosis and angiogenesis (Alexander 
et al., 2001; Andarawewa et al., 2003; Ha et al., 2001; Lee et al., 2000).   These 
processes occur at some stages in normal development, and during pathological 
conditions such as tumor progression and metastasis.   Invasion requires active 
degradation of the extracellular matrix and basement membrane, which requires the 
actions of MMPs.   Not surprisingly, over-expression of MMP3 in the mouse mammary 
gland causes increased lateral branching, precocious alveolar development, hyperplasia, 
EMT and cancer (Sympson et al., 1994 & 1995).   MMP3 gene expression is primarily 
regulated at the promoter level and is induced by growth factors, cytokines, ECM 
components and EMT-dependent transcription factors like SLUG and SNAIL 
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(Chakraborti et al., 2003; Miyoshi et al., 2005, Miyoshi et al., 2004).   We have found 
that re-expression of SIM2s decreases MMP3 mRNA levels by transcriptional repression 
of the MMP3 promoter through inhibition of AP-1 binding.   This is consistent with 
other tumor suppressor genes such as the tumor metastasis suppressor nm23-H1, which 
inhibits invasion and metastasis by competing for and blocking activator binding to the 
YB1 response element on the MMP2 promoter (Cheng et.  al., 2002).   Similarly, 
expression of the ETS transcription factor TEL, abrogates RAS transformed NIH 3T3 
cell growth and tumorigenicity by suppressing MMP3 mRNA and promoter activity 
(Fenrick et.  al., 2000).   
     Our results are surprising since others have proposed that SIM2s is a tumor marker 
gene found to be up-regulated in prostate and pancreatic tumors (Benard et al., 2005; 
DeYoung et al., 2002; 2003a & 2003b).  The observation that SIM2s may have 
contradictory roles in cancer progression is not unique.   For example, in breast, ovarian 
and lung cancers, reduced caveolin-1 (CAV1) expression has been found to be 
associated with increased invasiveness and histological grade (Williams & Lisanti, 2005).   
This is supported by in vivo studies, which showed that mammary glands from Cav1-/- 
mice undergo precocious alveolar development, hyperplasia and increased incidence of 
tumor formation (Williams et al., 2004).   In contrast, CAV1 is upregulated in metastatic 
bladder, thyroid and prostate carcinomas (Pflug et al., 1999; Williams et al., 2005).   One 
possibility is that CAV1 is transiently down-regulated in migrating cells and re-
established after intravasation.   Perhaps there are tissue-specific differences in ancillary 
factors modifying CAV1 effects.   Alternatively, it is possible that deletion of, or 
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mutations in, down-stream targets of CAV1 signaling could account for these 
differences.   At present, very little is known about the function of SIM2, and even less 
is known about SIM2s.   Thus, it is possible that the discrepancies between our results 
and those of DeYoung et al.  may be due to similar, as yet uncharacterized phenomena.   
     The unique profile of cancer risk in DS individuals suggests that more than one gene 
may be responsible for the observed differences in cancer susceptibilities.   Most likely, 
these effects are the result of complex interactions between gene products encoded by 
chromosome 21 and downstream targets of these genes on other chromosomes.   
Chromosome 21 contains over 300 genes, of which many have been implicated as 
playing a role in the DS-associated cancer promotion or protection effects.   A recent 
report linked the increased incidence of DS acute megakaryoblastic leukemia to the 
transcription factor GATA1 (Greene et al., 2003; Wechsler et al., 2002).   Another 
putative oncogene located on chromosome 21, ETS2, has been shown to be up-regulated 
in testicular germ cell tumors from DS subjects (Stage et al., 1997).   Interestingly, 
despite evidence suggesting that ETS2 plays a role in breast cancer progression, over-
expression of ETS2 in DS individuals is not associated with increased breast cancer 
incidence.   
     The tumor suppressive activity of trisomy 21 may be the result of changes in 
extracellular matrix (ECM) and angiogenic regulators.   Several genes regulating ECM 
composition have been linked to chromosome 21 including collagen 6a (COL6A), 
superoxide dismutase 2 (SOD2), ß2 integrin (ITGB2) and endostatin (COL18A1) 
(Benard et al., 2005; Zorick et al., 2001).   In addition, it has recently been shown that 
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the DS critical region-1 protein (DSCR-1) is induced by VEGF and inhibits thrombin 
and VEGF signaling ultimately blocking endothelial proliferation and angiogenesis 
(Minami et al., 2004).   Our results suggest that SIM2s contributes to the breast cancer-
protective effects of DS by inhibiting breast cancer growth.   In addition, we have found 
that SIM2s abrogates breast cancer cell invasion and MMP3 gene expression, implying 
that SIM2s may also function as a metastasis inhibitor. 
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V. FURTHER STUDIES 
 
     In this study, we found that SIM2s is decreased in breast cancer patients and 
differentially expressed in human breast epithelial and breast cancer cell lines with low 
levels observed in highly invasive MDA-MB-435 and MDA-MB-453 cell lines.  
However, the mechanism by which SIM2s is silenced in highly invasive breast cancer 
cells is unknown.  Further studies are needed to decipher the mechanism of SIM2 
suppression in breast cancer.   We currently are taking a closer look at epigenetic 
mechanisms, such as hypermethylation, deacetylation, increased degradation, and 
mislocalization. 
     The effects of Sim2s overexpression in the mammary gland also need to be 
determined.  Dominant gain of function experiments utilizing transgenic mice have 
proven useful in elucidating the roles of mammalian gene products in development and 
cancer.  Thus, Developing MMTV-mSim2s transgenic mice will be beneficial to 
examine the role of Sim2s in mammary development and breast cancer.   This can be 
accomplished by placing mSim2s under the control of the long terminal repeat of the 
mouse mammary tumor virus (MMTV), which directs expression to the mammary gland.   
     The role of Sim2s in mammary tumor initiation and progression can be determined 
by crossing Sim2s heterozygous and MMTV-mSim2s overexpressing mice with 
mammary cancer prone MMTV-Neu and MMTV-Myc transgenic animals.  MMTV-Neu 
mice develop multi-focal metastatic mammary tumors after a relatively short latency 
period, whereas MMTV-Myc mice exhibit an extended latency period (Muller et al., 
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1988; Stewart et al., 1984).   MMTV-Myc tumors arise as stochastic foci within normal 
breast tissue; however, other factors are required to convert the tumor foci to a metastatic 
state.   By using these two models of tumorigenesis, it will be possible dissect pathways 
involved in Sim2s-mediated tumor suppression. 
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VI. SUMMARY 
 
     SIM is a member of basic helix-loop-helix Per-ARNT-Sim (bHLH-PAS) family that 
actives midline gene transcription and represses lateral CNS gene transcription.  In 
humans, SIM2 is involved in the etiology of the Down’s phenotype.  Interestingly, 
women with DS are 10-25 times less likely to develop breast cancer.  Women with DS 
rarely become pregnant, increasing their risk for breast cancer; however, they experience 
earlier menopause, leading to a decrease in risk.   Thus, hormonal factors alone are 
unlikely to explain the significantly decreased rate of breast cancer and protective factors 
are more likely to be genetically linked.  These observations have led to the hypothesis 
that one or more tumor suppressor genes are present on chromosome 21 and prevent 
cancer development by gene dosage effect.  Based on its role in the CNS midline 
development and its relation with DS, SIM2 was considered as a potential candidate. 
      In this study, we have shown that mouse Sim2s is less potent than full length Sim2 at 
repressing HIF1-α, and can activate expression of a gene controlled by the Drosophila 
toll gene CME via ARNT's transactivation domain.  Sim2s is just as repressive as Sim2 
on TCDD-mediated gene expression through a DRE and is able to increase expression of 
a CME-controlled gene.  In contrast, Sim2s can activate expression from a CME 
apparently by acting as a docking protein for ARNT.  This implies that the Pro/Ala-rich 
sequence present in Sim2, but not Sim2s, exerts a negative effect on CME-mediated 
gene expression. 
     We found that Sim2s is the predominant form of Sim expressed in the mouse 
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mammary gland, and its expression is tightly regulated during adolescent development 
and throughout pregnancy.   These data support our hypothesis that Sim2s plays an 
important role during mammary gland development and differentiation. 
     We found that forced expression of SIM2s in MDA-MB-435 cells significantly 
inhibited proliferation, anchorage-independent growth and invasion potential.  In 
addition, loss of Sim2s in the mammary gland resulted in dramatically increased ductal 
branching, accelerated lobuloalveolar-like precocious hyperplasia, and decreased cell 
apoptosis suggesting that SIM2s is a mammary tumor suppressor. 
     Sim2-/- mammary glands lose E-cadherin expression and contain hyperplastic 
nodules, suggesting that Sim2s plays a role in regulating E-cadherin/ß-catenin signaling.  
In SIM2s infected MDA-MB-435 cells, decrease in invasion appears to be due, in part, 
to SIM2s' ability to repress MMP3 expression through direct inhibition of AP-1 binding 
to the MMP3 promoter.  Our results suggest that SIM2s contributes to the breast cancer-
protective effects of DS by inhibiting breast cancer growth.   In addition, we have found 
that SIM2s abrogates breast cancer cell invasion and MMP3 gene expression, implying 
that SIM2s may also function as a metastasis inhibitor. 
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